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ABSTRACT
Koesters, Andrew G. Ph.D. Biomedical Sciences PhD Program, Wright State
University, 2014. Rab3A as a Modulator of Homeostatic Synaptic Plasticity.

The nervous system is faced with perturbations in activity levels
throughout development and in disease or injury states. Neurons need to adapt
to these changes in activity, but also need to maintain circuit firing within a
normal range to stabilize the network from becoming too excited or too
depressed. Homeostatic synaptic plasticity, the compensatory increase or
decrease in synaptic strength as a result of excessive circuit inhibition or
excitation, is a mechanism that the nervous system utilizes to keep network
activity at normal levels. Despite intense effort, little is known about the
mechanisms underlying homeostatic synaptic plasticity. Numerous studies have
implicated postsynaptic modulation of AMPA receptors, but disagreement exists
as to which receptor subtype, GluR1 or GluR2, predominates. Here, we
demonstrate the completely novel finding that a presynaptic protein, Rab3A, a
small GTPase that binds synaptic vesicles by switching between its active GTPbound form and its inactive GDP-bound form, is essential for the regulation of
homeostatic synaptic plasticity in dissociated mouse cortical neuron cultures.
Using a combination of electrophysiology, pharmacology, and
immunohistochemistry, we show that multiple mechanisms exist to increase
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synaptic strength in response to chronic activity deprivation, including but not
limited to modulation of GluR1 and GluR2-containing AMPA receptors. Despite
the variability and complexity of underlying mechanisms mediating the change in
synaptic strength, we consistently found that modulation of synaptic strength in
response to chronic network activity deprivation was completely lost in the
absence of neuronal Rab3A, and that loss of Rab3A prevented the homeostatic
increase in GluR2 levels but not GluR1. We conclude that there exist a biphasic
mechanism for homeostatic synaptic plasticity, as suggested for LTP, where the
induction (Phase 1) of the homeostatic increase in synaptic strength is first due to
increasing GluR1-containing AMPA receptors, which is then followed by a
Rab3A-dependent switch to GluR2-containing AMPA receptors to maintain the
increase in synaptic strength (Phase 2).
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I. INTRODUCTION

Synaptic Plasticity
The nervous system is continuously confronted with altering states of
activity. Numerous studies over many years have demonstrated that the nervous
system is exceptionally proficient in responding to varying degrees of stimuli to
remodel its circuitry in order to respond and adapt to the dynamic stream of
synaptic activity. This process of activity-dependent modifications in synaptic
physiology is called synaptic plasticity. Effective functioning of this process
underlies normal nervous system functions such as movement, thinking, learning
and memory, and perception, but malfunction of this system could trigger a
variety of psychiatric and neurological disorders, possibly resulting in epilepsy,
schizophrenia, or Alzheimer’s disease.
Synaptic plasticity occurs in at least two forms that have opposing effects
on synaptic physiology. The first is Hebbian plasticity, which includes long-term
potentiation (LTP) and long-term depression (LTD), and induces rapid, longlasting changes at individual synapses in response to altered activity. LTP is
induced by high frequency bursts of activity that strengthen synapses and LTD is
induced by persistent, low frequency activity to weaken synapses. This form of
synaptic plasticity is believed to be the basis for learning and memory. If left
unchecked LTP and LTD may promote network instability because as synaptic
1

strength increases unchecked at individual synapses runaway excitiation could
occur, and unregulated depression at single synapses may cause those
synapses to drop out of the network. The second form is homeostatic synaptic
plasticity, the nervous system’s response to long-lasting, chronic perturbations in
synaptic activity. This type of plasticity is induced by chronic perturbations to
network activity and affects synaptic networks globally to maintain synaptic
activity within a desired range in a compensatory manner to guard against
network hyperexcitation and silencing.

Hebbian Plasticity
Donald Hebb first proposed his theory on the function of neurons and
psychological processes, such as learning and memory, in 1949. This later
became the basis for Hebbian synaptic plasticity, which more specifically
includes LTP and LTD.
Long-term potentiation is the persistent increase in synaptic strength of an
excitatory postsynaptic neuron as a result of high-frequency stimulation of a
synaptically connected presynaptic neuron. Induction of LTP requires the
activation of N-methyl-D-aspartate (NMDA) receptors (Bliss and Collingridge,
1993) via postsynaptic depolarization due to cation influx through α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Malenka and
Nicoll, 1999). AMPA receptors are ionotropic and are responsible for the majority
of excitatory neurotransmission in the brain. NMDA receptors are also ionotropic
but are blocked by Mg2+ at resting membrane potentials until sufficient
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postsynaptic depolarization removes the block allowing Ca2+ influx. Activation of
NMDA receptors and the subsequent influx of Ca2+ into the postsynaptic neuron
results in an increase in the dendritic spine Ca2+ concentration triggering second
messenger activation and a signaling cascade to recruit more AMPA receptors
into the postsynaptic membrane. Ca2+/calmodulin-dependent protein kinase II
(CamKII) has been implicated as a major player in NMDAR-dependent LTP
induction (Lisman et al., 2002; Malenka and Nicoll, 1999). Other potential
signaling molecules involved in LTP include other kinases, such as protein
kinase A (PKA) (Lynch, 2004), protein kinase C (PKC) (Bliss and Collingridge,
1993; Hu et al., 1987; Linden and Routtenberg, 1989; Malenka and Nicoll, 1999;
Malinow et al., 1989), protein kinase M zeta (PKMζ) (Hrabetova and Sacktor,
1996; Ling et al., 2002), proto-oncogene tyrosine-protein kinase (Src) (Salter and
Kalia, 2004), mitogen-activated protein kinase (MAPK), which activates
extracellular signal-related kinases (ERKs) (Sweatt, 2004; Thomas and Huganir,
2004), and phosphatidylinositide 3-kinase (PI3 kinase), an important molecule for
trafficking of AMPA receptors to hippocampal synapses in dissociated cultures
(Man et al., 2003). The trafficking of AMPA receptors to the synapse has been
clearly demonstrated to be important for the expression and maintenance of LTP
(Malenka and Bear, 2004; Malinow and Malenka, 2002; Shi et al., 2001).
The expression of LTP has been the focus of intense research and initially
there was intense debate over whether it was due to a pre- or postsynaptic
mechanism. Presynaptic mechanisms would involve changes affecting the
release of neurotransmitter, such as increases in vesicle loading of transmitter
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and increases in the probability of release (Ho and Shen, 2011; Malinow and
Tsien, 1990). Postsynaptic mechanisms would involve synaptic modifications to
postsynaptic receptors, such as increased insertion of AMPA receptors to
enhance responsiveness to a stimulus. Ultimately, evidence accumulated that
the mechanism of increasing AMPAR numbers in response to activity-dependent
changes is the major mechanism in the expression of LTP (Bredt and Nicoll,
2003; Ho and Shen, 2011; Malenka and Nicoll, 1999; Malinow and Malenka,
2002; Song and Huganir, 2002). These changes in AMPA receptor heterotetramers composed of four subunits, GluR1-4 (Greger et al., 2007) expression appears to be due to phosphorylation of these receptors (Malenka
and Bear, 2004), specifically the GluR1 subunit and its phosphorylation by
CamKII, which triggers the insertion of receptors in the synaptic membrane
(Hayashi et al., 2000; Lee et al., 2003).
Late-phase maintenance of LTP requires protein synthesis and gene
transcription (Abraham and Williams, 2003; Lynch, 2004; Pittenger and Kandel,
2003), but another theory is that synapses that have undergone LTP exhibit
anatomical remodeling to preserve the changes in synaptic strength (Malenka
and Bear, 2004). These changes include growth of new dendritic spines,
increases in the size of existing spines, and the splitting of spines into two
functional synapses (Abraham and Williams, 2003; Yuste, 2011). Molecular
mechanisms affecting these structural changes have received considerable
attention and when postsynaptic scaffolding proteins are overexpressed in
dissociated cultures, there is an increase in dendritic spine size (Hering and
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Sheng, 2001). This has lead to a model of LTP where the induction involves
insertion of GluR1 AMPA receptors followed by the accumulation of scaffolding
proteins into the postsynaptic density (PSD) resulting in an increase in spine and
PSD size (Lisman and Zhabotinsky, 2001; Luscher et al., 2000). This model
suggests that LTP first involves an increase in synaptic strength followed by
growth of the synapse.
Long-term depression (LTD) is the long-lasting decrease in synaptic
strength due to low-frequency stimulation of paired excitatory neurons. As with
LTP, LTD induction requires both AMPA and NMDA receptor activation (Dudek
and Bear, 1992; Mulkey and Malenka, 1992) and the subsequent increase in
NMDAR-mediated Ca2+ influx. However, unlike LTP where the rise in [Ca2+] is
large and sudden, Ca2+ entry to trigger LTD is slower and less drastic (Mulkey
and Malenka, 1992). This slow, persistent rise in [Ca2+] activates serinethreonine protein phosphatases that de-phosphorylate AMPA receptors triggering
their removal from the cell surface (Mulkey et al., 1994; Mulkey et al., 1993)
(Mulkey and Malenka, 1992). Induction of LTD is blocked by phosphatase
inhibitors that target calcineurin and protein phosphatase 1 (PP1) in the
postsynaptic cell (Kirkwood and Bear, 1994; Mulkey et al., 1994; Mulkey et al.,
1993). As in LTP, LTD expression and maintenance are reliant on AMPA
receptors. De-phosphorylation of AMPA receptors, specifically the GluR1containing subtype, decreases channel open probability (Banke et al., 2000), and
also underlies the loss of AMPA receptors at synapses by internalizing them via
a clathrin-mediated process (Beattie et al., 2000). Postsynaptic density protein
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95 (PSD-95), a protein involved in the docking of AMPA receptors in the
postsynaptic membrane, is directly bound to the postsynaptic membrane by
palmitoylation and also binds stargazin, a protein demonstrated to traffic AMPA
receptors to synapses (Chen et al., 2000; Schnell et al., 2002). As evidenced by
the overexpression and removal of PSD-95 from the synapse, AMPAR numbers
increase and decrease, respectively (Schnell et al., 2002).
Long-term potentiation and long-term depression are widely believed to be
the major cellular mechanism for learning and memory by rapidly fine-tuning
individual synapses based on their experiences. This constant strengthening
and weakening of synapses has the potential, if left unregulated, to generate an
unstable network.

Homeostatic Synaptic Plasticity
Homeostatic synaptic plasticity, a negative feedback mechanism, was first
described in 1998 as a global compensatory change in synaptic strength
resulting from chronic perturbations to neuronal network activity (O'Brien et al.,
1998; Turrigiano et al., 1998) and is proposed to protect against network
instability that may be produced by LTP and LTD (Pozo and Goda, 2010). When
the Na+ channel blocker, tetrodotoxin (TTX), was applied to rat cortical neuron
cultures for 48 hours to block all action potentials and chronically silence all
synaptic activity, there was an enhancement in synaptic strength as evidenced
by the increase in the amplitude of the postsynaptic response to a single vesicle
release of neurotransmitter - miniature excitatory postsynaptic currents
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(mEPSCs) - of pyramidal neurons (Turrigiano et al., 1998). The converse effect
was observed on mEPSC amplitude when bicuculline, a GABAA receptor
antagonist, was applied to cultures for 48 hours to block all inhibitory
transmission to cause global network hyperexcitation resulting in decreased
mEPSC amplitude (Turrigiano et al., 1998). The same compensatory effects
were seen on cultured spinal neuron mEPSC amplitudes when AMPA receptor
antagonists (to block all excitatory neurotransmission) or GABAA and kainate
receptor antagonists (to increase basal excitatory synaptic activity) were
chronically applied to cultures, and these changes in mEPSC amplitude were
accompanied with an accumulation or decrease in synaptic AMPA receptors,
respectively (O'Brien et al., 1998). Unlike many forms of synaptic plasticity that
require Ca2+ influx via postsynaptic NMDA receptors (Linden and Connor, 1995),
the change in synaptic strength was, at least, in part due to AMPA receptor
signaling, because cultures grown in the presence of the NMDA receptor
antagonist, D (-)-amino-7-phosphonovalenic acid (AP5) for 48 hours resulted in
no change in mEPSC amplitude or frequency, while 48 hour AMPA receptor
blockade via 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) produced the same
results observed with TTX (Turrigiano et al., 1998).
Numerous studies since this groundbreaking discovery have focused on
determining the mechanism of homeostatic synaptic plasticity, which in contrast
to our extensive information on LTP and LTD mechanisms, is still not well
understood. Several possibilities exist as to where the site of synaptic strength
could be modulated by the nervous system. Presynaptic mechanisms that could
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regulate synaptic strength include varying the number of synaptic vesicles being
exocytosed or by altering the amount of neurotransmitter being loaded into a
single vesicle (Pozo and Goda, 2010; Rich and Wenner, 2007). For example, a
decrease in network activity could activate a compensatory response mechanism
that increases the number of exocytosed vesicles and/or increases the amount of
neurotransmitter loaded into each vesicle resulting in an increase of synaptic
strength, and vice versa if the network becomes hyperactive (Figure 1, #3 and
#1, respectively). The idea of increased vesicle exocytosis after chronic silencing
is unlikely to produce a homeostatic change in mEPSC amplitude because
frequency of mEPSC events would be expected to increase, which is not usually
seen in homeostatic plasticity, and the improbable simultaneous fusion of
vesicles would have to occur to produce an increase in mEPSC amplitude.
Another potential mechanism for homeostatic plasticity that has received the
most consideration and has been extensively studied, involves the bidirectional
trafficking of glutamate receptors, specifically AMPA receptors (Figure 1, #2 and
#4). Several studies have demonstrated that in response to a variety of chronic
activity perturbations, AMPA receptors are trafficked to and from the postsynaptic
neuron’s membrane in a compensatory manner (Aoto et al., 2008; Correa et al.,
2012; Evers et al., 2010; Fu et al., 2011; Gainey et al., 2009; Soden and Chen,
2010; Stellwagen and Malenka, 2006; Wierenga et al., 2005).

GluR1 vs. GluR2 AMPA Receptors in Homeostatic Synaptic Plasticity
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As mentioned earlier, AMPA receptor trafficking to and from the synapse
in response to chronic activity perturbations has been well-established to be an
important mechanism for the expression of homeostatic plasticity, but
discrepancies exist as to which receptor subtypes are involved. Some studies
have shown that homeostatic synaptic plasticity requires the increased insertion
of the GluR2-containing receptors into the postsynaptic membrane in response to
activity deprivation (Cingolani et al., 2008; Gainey et al., 2009) while others have
demonstrated an increase in surface GluR1-containing AMPA receptors (Ju et
al., 2004; Stellwagen et al., 2005; Sutton et al., 2006; Thiagarajan et al., 2005),
and some have shown increases in both GluR1 and GluR2 (Sun and Wolf, 2009;
Wierenga et al., 2005). The differences between which subunit is involved may
be due to different experimental conditions, such as species (rat vs. mouse), age
of the culture (1 week vs. 2 week), type of activity block (TTX vs. receptor block),
length of activity block (24 hours vs. 48 hours), or cell type (Table 1), possibly
demonstrating the existence of multiple types of homeostatic plasticity. Another
possibility is that a two-step process exists where GluR1-containing AMPA
receptors are first inserted into the membrane followed by increased expression
of GluR2-containing AMPA receptors, as suggested for LTP (Plant et al., 2006).

Glia and Homeostatic Synaptic Plasticity
More recently, glia have been implicated in homeostatic plasticity
(Stellwagen and Malenka, 2006). Glia have long been considered to be merely
support cells of neurons in the nervous system, but have now been shown to
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release tumor necrosis factor-α (TNFα) (Beattie et al., 2002) and glypican-4
(Allen et al., 2012) to influence synaptic strength by increasing cell surface
expression of GluR1-containing AMPA receptors (Allen et al., 2012; Stellwagen
et al., 2005) and glial TNFα has been demonstrated to be essential for
homeostatic synaptic plasticity (Stellwagen and Malenka, 2006). Glial release of
factors that are capable of increasing synaptic strength in a homeostatic manner
by upregulating AMPA receptors into the postsynaptic membrane make them an
intriguing candidate as a potential sensor for network activity.

Rab3A: A Small GTPase
Rab proteins are monomeric GTPases that form the largest branch of the
Ras superfamily of small GTPases and exist in all eukaryotic cells (Lang and
Jahn, 2008; Takai et al., 2001). More than 60 members of Rabs have been
identified in mammalian cells (Lang and Jahn, 2008) and these proteins regulate
intracellular vesicle trafficking (Takai et al., 2001). Rabs serve as a “switch” by
cycling between their active GTP-bound form, where they associate with vesicles
and assist in vesicle trafficking to the cell membrane, and their inactive GDPbound form, where they dissociate from vesicles and localize to the cytosol
(Figure 2).
Rab3 is highly expressed in the brain (Pavlos et al., 2010) and Rab3A is
overwhelmingly the most abundant isoform located at synapses (Fischer von
Mollard et al., 1990). The Rab3 subfamily, which encompasses Rab3A, Rab3B,
Rab3C, and Rab3D, has been extensively studied in synaptic function and
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secretion, and the four highly homologous isoforms, which share as much as
84% homology (Cheng et al., 2002), have overlapping and redundant functions in
vesicle exocytosis (Jahn, 2004; Pavlos and Jahn, 2011). Despite evidence
supporting Rab3A’s role in synaptic vesicle exocytosis, its exact function is still
unclear. Deletion of Rab3A (Rab3A-/-) results in mice that are viable and fertile
(Schluter et al., 2004), and is not essential for exocytosis but rather may be
important for regulating synaptic function and efficiency (Geppert et al., 1994;
Geppert et al., 1997). On the other hand, knockout of Rab3A in conjunction with
any of the other two isoforms is lethal, while triple Rab3B, Rab3C, and Rab3D
knockout animals were viable and fertile (Schluter et al., 2004). Quadruple
knockouts develop normally but die shortly after birth due to respiratory failure,
have no changes in hippocampal synaptic morphology or mEPSC properties, but
do exhibit a 30% decrease in evoked responses of cultured hippocampal
neurons that appears to be due to a decrease in release probability (Schluter et
al., 2004). Rab3A has also been demonstrated to be necessary for PKAdependent presynaptic form of LTP at mossy fiber-CA3 synapses in the
hippocampus (Castillo et al., 1997) and Rab3A-/- hippocampal neurons do not
respond to BDNF-induced potentiation of evoked synaptic currents (ThakkerVaria et al., 2001). These results suggest that Rab3A is not critical for vesicle
exocytosis, but is required for some forms of plasticity of release probability.
More recently, the Engisch and Rich labs have shown that Rab3A is
important for homeostatic synaptic plasticity at the mouse neuromuscular
junction (NMJ). The Rab3A earlybird mouse (Rab3Aebd/ebd), named for its
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shortened circadian rhythm, expresses a point mutation, D77G, in the Rab3A
guanine nucleotide-binding regions. The mutation decreases the ability of
Rab3A to bind both GDP and GTP (Yang et al., 2007) and homeostatic
regulation of synaptic strength at the NMJ is abolished in these animals (Wang et
al., 2011). Also, the homeostatic increase in synaptic strength at the NMJ is not
accompanied by an increase in vesicular acetylcholine transporter, VAChT, or by
an increase in postsynaptic acetylcholine receptors (Wang et al., 2011). These
results differ from what is generally thought to occur for homeostatic plasticity at
central synapses where the increase in synaptic strength is accompanied by an
increase in postsynaptic AMPA receptors (Table 1) and/or VGLUT1 expression
(Buckby et al., 2006). Interestingly, the ablation of Rab3A (Rab3A-/-) at the NMJ
did not abolish, but did diminish, the response to activity blockade at these same
synapses suggesting that other Rab3A isoforms which are present (Wang et al.,
2011) may compensate for the loss of Rab3A. The finding that a presynaptic
protein is important for modulating homeostatic synaptic plasticity at the mouse
NMJ is surprising since the prevailing view from studies performed in primary
cultures of hippocampal and cortical neurons is that homeostatic plasticity is due
to the bi-directional regulation and trafficking of postsynaptic AMPA receptors in
response to altered network activity. A possible explanation for this could be that
the mechanism for homeostatic plasticity is different at the NMJ than in the brain.
We will address this possibility in Specific Aims 1 and 2.

Rab3A and Disease
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Researchers looking at the synaptic pathology of Alzheimer’s Disease
(AD) found that Rab3A expression was reduced in both the hippocampus and in
the frontal cortex of AD patients and that in these AD patients lower Rab3A levels
were found with both increasing duration and severity of dementia (Blennow et
al., 1996). Levels of Rab3A in brain tissue from AD patients are reduced in
conjunction with the known AD-associated proteins, presenilin-1 and amyloid
precursor protein (APP), and the reduction of these proteins are restricted to
areas of the brain known to degenerate in AD (Davidsson et al., 2001). More
recently, Rab3A has been shown to be required for the assembly of a distinct
type of vesicle involved in the transport of APP for cleavage by α-secretases
(Szodorai et al., 2009). Together, these data demonstrate a correlation between
Rab3A expression and severity of dementia in AD patients and a functional role
of Rab3A activity in regulating the transport of an AD-associated protein, APP.
In addition to AD, Rab3A has been linked to several other disorders of the
nervous system. Rab3A expression is reduced in the thalamus, the
hippocampus, and the frontal and parietal cortex of post-mortem brains of
schizophrenic patients (Davidsson et al., 1999), and is also decreased in the
dorsolateral prefrontal cortex of patients with major depressive disorder (Kang et
al., 2012). Rab3A has also been demonstrated to regulate the membrane
association and dissociation of α-synuclein, a protein known to accumulate in
Lewy bodies in Parkinson’s Disease (Chen et al., 2013) suggesting that
impairments of α-synuclein interactions with Rab3A and synaptic vesicles may
play a role in neurodegeneration. Deletion of Rab3A rescues the epileptic
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phenotype seen in synapsin II knockout mice (Coleman and Bykhovskaia, 2010).
The loss of Rab3A impairs glutamatergic excitatory synaptic transmission
resulting in the restoration of the excitatory/inhibitory balance that is shifted to an
overexcitable phenotype in the absence of synapsin II (Feliciano et al., 2013).
Finally, another link between Rab3A and neurological disease is that Rab3A is
an mRNA cargo of the translational regulator and RNA transporter, Fragile X
mental retardation protein (Miyashiro et al., 2003) and its expression is
decreased in cortical neuron synapses of the Fmr1 knockout mouse, a model
mouse of Fragile X syndrome (Annangudi et al., 2010).
It is reasonable to believe that if the homeostatic balance and stability in
neuronal activity is not maintained, it could lead to or complicate many disorders
and diseases of the nervous system, including mental retardation and autism
(Ramocki and Zoghbi, 2008; Toro et al., 2010). One example is the Fragile X
mental retardation protein, or FMRP, which has been linked to Fragile X
syndrome and mental retardation, and has been shown to be essential for
retinoic acid-dependent homeostatic increases in synaptic strength in response
to neuronal silencing by TTX in the mouse hippocampus (Soden and Chen,
2010).
Disregulation of homeostatic synaptic plasticity has been associated with
several diseases and disorders of the nervous system, schizophrenia (Dickman
and Davis, 2009), Alzheimer’s disease (Pratt et al., 2011), epilepsy (Houweling et
al., 2005), and Fragile X mental retardation (Soden and Chen, 2010).
Determining the regulatory function of Rab3A, a synaptic protein implicated in
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many neurological and psychiatric diseases would have major clinical
applications by providing for a new therapeutic target in several nervous system
diseases. Here, we present the first evidence that Rab3A, a presynaptic
molecule, is required for homeostatic synaptic plasticity. Together these studies,
and what is known about Rab3A, suggest Rab3A interacts with multiple
neurological disease-associated mechanisms, although whether it is combating
or contributing to pathology is unclear. The fact that Rab3A has been
demonstrated to be important for homeostatic synaptic plasticity at the
NMJ, leads us to hypothesize that the presynaptic protein, Rab3A, is
required for regulating synaptic strength in homeostatic plasticity at
central synapses (Specific Aim 1).

II. MATERIALS AND METHODS

The methods described below are common to all Aims except where
noted. Methodology specific to an Aim will be described with that particular Aim.

Animals – Rab3A Colony
Rab3A heterozygous (Rab3A+/-) were bred at Wright State University to
generate offspring consisting of homozygous wild-type Rab3A (Rab3A+/+),
homozygous knock-out of Rab3A (Rab3A-/-), and Rab3A+/-. Animals were
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genotyped via Rab3A-targeted PCR of tail DNA using the following primer
sequences:
TCC TGT GAC CTC CAA CTG TG (forward)
GGC CCA AAA CTG AGC AAC (reverse)
and the reaction parameters:
1. 96ºC for 2:00
2. 94ºC for 0:45
3. 58ºC for 0:45
4. 72ºC for 1:00
(repeat steps 2-4 for a total of 39 cycles)
5. 72ºC for 7:00
6. 4ºC hold
The PCR products were separated on a 3.5% agarose gel. The above PCR
protocol yielded a 178 base-pair Rab3A wild-type amplicon (Figure 3, right lane)
and a 170 base-pair Rab3A knock-out amplicon (Figure 3, left lane). Rab3A+/were determined by the presence of both the wild-type and knock-out amplicons
(Figure 3, center lane). Rab3A+/- progeny were bred to maintain the colony, while
final breedings of Rab3+/+ males with Rab3+/+ females and Rab3A-/- males with
Rab3A-/- females to produce homozygous litters to be used for experiments. All
experiments were performed on neuronal cultures prepared from newborn pups
on postnatal day 0 (P0) making it impossible to genotype these animals prior to
culture preparation. The homozygous breedings allowed for determination of
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genotypes of experimental animals. All animal procedures were approved by
Wright State University’s Laboratory Animal Care and Use Committee.

Animals – Rab3A earlybird Colony
The breeding strategy for the Rab3A earlybird (ebd) animals was the
same as described above: Rab3A+/ebd were bred to maintain the colony, while
Rab3A+/+ pairings and Rab3Aebd/ebd breedings were mated to produce Rab3A+/+
and Rab3Aebd/ebd progeny, respectively, for experiments. Due to the presence of
a single point mutation and the impossibility to simply screen for this via PCR, a
more elaborate two-step genotyping protocol was performed utilizing PCR to
amplify our region of interest followed by restriction digest of these amplicons
with Bsp 1286I to reveal the Rab3A ebd point mutation. The PCR protocol used
the following primers:
TGA CTC CTT CAC TCC AGC CT (forward)
TGC ACT GCA TTA AAT GAC TCC T (reverse)
in a PCR reaction to amplify the region of DNA that may contain the Rab3A ebd
point mutation. The reaction parameters were as follows:
1. 94ºC for 5:00
2. 94ºC for 0:30
3. 57ºC for 0:40
4. 72ºC for 1:00
(repeat steps 2-4 for a total of 35 cycles)
5. 72ºC for 10:00
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6. 4ºC hold
Two microliters of the 45 μl PCR reaction were ran out on a 1.0% agarose gel
and yielded a single product with a size of 557 base-pairs (Figure 4A). The
remaining 43 μl of PCR products were saved for further processing in the second
step of the genotyping protocol. The presence of a PCR amplicon was used to
demonstrate successful DNA amplification for the actual screening process by
restriction digest described below. Once it was determined that the PCR was
successful, the remaining PCR amplicons were purified and concentrated using
the QIAEX II Kit (Qiagen) according to the manufacturers protocol. Briefly, PCR
products were transferred to separate tubes and three volumes of Buffer QX1
were added to each tube. Then, 10 μl of QIAEX II were added to each tube and
incubated for 10 minutes at room temperature. Samples were vortexed every 2
minutes to maintain the QIAEX II in suspension. After the incubation period,
samples were centrifuged at 13,000 rpm for 30 seconds and the supernatant was
poured off leaving the pellet. The pellet was then washed twice with 500 μl of
Buffer PE and allowed to air dry completely until the pellet was white. After
drying, DNA was eluted by adding 20 μl of nuclease-free H2O, vortexed to resuspend the pellet, and incubated at room temperature for 5 minutes. Each
sample was then centrifuged at 13,000 rpm for 1 minute and supernatant
containing the purified and concentrated DNA was transferred to clean tubes.
Samples were then subjected to restriction digest via the restriction enzyme Bsp
1286I (New England Biolabs, Ipswich, MA) per the manufacturers protocol. After
restriction digest, samples were ran out on a 3.0% agarose gel yielding 402 and
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155 base-pair bands for Rab3A wild-type (earlybird colony) (Figure 4B, left lane)
and 402, 104, and 51 base-pair bands for the Rab3A earlybird mutation (Figure
4B, right lane). Heterozygotes were determined by the presence of all the bands
(Figure 4B, center lane).

Primary Culture of Mouse Cortical Neurons
Dissociated cultures of mixed neuronal and glial populations were
prepared from P0 Rab3A-/- and Rab3Aebd/ebd neonates, and compared with
cultures from wild-type mice from their respective colonies. Wild-type cultures
were produced from each heterozygote colony due to the different genetic
backgrounds of the Rab3A KO and Rab3A ebd mice. Each culture was prepared
from cortices harvested from two animals. Pups were euthanized by decapitation
and brains were quickly removed from the skull and pinned at the cerebellum to a
chilled Sylgard petri dish. To prevent contamination of cortical neurons with
hippocampal neurons, the hippocampi from both hemispheres were removed and
discarded and cortices were dissected out and placed into 1 ml of chilled
Neurobasal-A media (Gibco), osmolarity adjusted to 270 mOsm, and
supplemented with DNAse (Fisher ThermoScientific). Tissue digestion was
carried out by the addition of papain (Worthington Biochemical) at 20 units/ml
and incubated in a 37°C H2O bath for 20 minutes with gentle stirring. After
digestion, cortices were triturated very gently 3-5 times with a fire-polished
Pasteur pipette, filtered through a 100 μm cell strainer (Corning Falcon) to
remove chunks of tissue, and transferred to a clean, sterile 15 ml conical tube.
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The cell suspension was then centrifuged at 1100 rpm for 2 minutes, supernatant
was carefully removed and discarded, and the pellet resuspended with room
temperature Neurobasal-A media (270 mOsm), supplemented with 5% fetal
bovine serum (FBS; promotes glial growth but is toxic to neurons), 2% B-27
supplement to promote neuronal growth (Gibco), L-glutamine, and gentamicin.
Neurons were counted and plated onto 12 mm coverslips pre-coated with poly-Llysine (Corning) to produce a high density culture. The culture media for the first
day (0 DIV) was the same as the above Neurobasal-A media supplemented with
FBS, B-27, L-glutamine, and gentamicin, and was switched after 24 hours (1
DIV) to media consisting of Neurobasal-A (270 mOsm), 2% B-27, and Lglutamine and FBS was excluded to avoid its toxic effects on neuronal viability
and health (Stellwagen and Malenka, 2006). Cells were maintained in culture for
13-14 DIV and half of the media was changed twice weekly and experiments
were performed at 13-14 DIV. Two days prior to experiments, TTX (500 nM;
Tocris), a potent Na+ channel blocker, was added to some cultures to chronically
silence all network activity and induce homeostatic synaptic plasticity
mechanisms, while sister cultures not receiving TTX treatment served as
untreated controls.

Whole-Cell Voltage Clamp to Record mEPSCs
At 13-14 DIV, mEPSCs from TTX-treated and control sister cultures of
Rab3A+/+ or Rab3A-/- neurons from the Rab3A+/- colony, or Rab3A+/+ or
Rab3Aebd/ebd neurons from the Rab3A+/ebd colony were recorded from via whole-
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cell voltage clamp to assess the role of Rab3A in homeostatic synaptic plasticity.
Recordings were taken from pyramidal neurons, which were identified visually as
those cells exhibiting a prominent apical dendrite; images were taken of all cells
recorded from (Figure 5). Cells were continuously perfused with a solution
consisting of (in mM): NaCl (115), KCl (5), CaCl2 (2.5), MgCl2 (1.3), dextrose
(23), sucrose (26), HEPES (4.2), and pH = 7.2 (Stellwagen and Malenka, 2006).
On the day of the experiment, the osmolarity of the media from the cultures was
measured (normally 285 – 295 mOsm) and the perfusate osmolarity was
adjusted to match the culture osmolarity to guard against osmotic shock to the
neurons. To isolate glutamatergic mEPSCs, TTX (500 nM) and picrotoxin (50
μM) were included in the perfusion solution to block action potentials and
GABAergic currents, respectively. Patch electrodes (3.5 – 5 MΩ) were filled with
an internal solution containing (in mM): K-gluconate (128), NaCl (10), EGTA (1),
CaCl2 (0.132), MgCl2 (2), HEPES (10), and pH = 7.2. Osmolarity was adjusted to
10 mOsm less than the perfusion solution osmolarity. Neurons were clamped at
a voltage of -60 mV using an Axopatch 200B patch-clamp (Axon Instruments)
and recorded from for 2 – 5 minutes. Data were collected with Clampex 10.0
(Axon Instruments).

Data Analysis of mEPSCs
Mini Anaysis software (Synaptosoft) was used to identify mEPSCs and all
events above a threshold of 3 pA were included in the data. We obtained a
mean mEPSC amplitude for each neuron and, unless otherwise noted, n is the
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number of neurons . All data were pooled based on the experimental condition
from 2-10 separate cultures. Overall means for each condition were determined
from the pooled data and are presented as ±SEM for the number of neurons
indicated. mEPSC data were compared using an unpaired Student’s t-test and
statistical significance established at p < 0.05.
For cumulative probability distribution plots of mEPSC amplitude, the first
50 mEPSCs were selected per cell per experimental condition, pooled together,
and sorted in ascending order. Experimental mEPSC amplitude distributions
were plotted on the same graph as control mEPSC amplitude distributions for
comparisons of shifts in distributions.

mEPSC Recordings are AMPAergic
To determine that all events in our recordings of mEPSCs from neurons
were AMPAergic in nature and to eliminate the possibility of contamination of our
data with NMDA-mediated mEPSCs, we performed whole-cell voltage clamp on
wild-type control neurons in the presence of the AMPA receptor blocker, CNQX
(10 μM). The experiment was done as follows; dissociated cultures of mixed glial
and neuronal populations from Rab3A+/+ mouse cortex were set up as described
above, were not chronically treated with TTX, and were recorded from at 13 DIV.
Baseline neuronal activity was determined by whole-cell voltage clamp, as
described above, for 2 minutes and were performed in the presence of TTX (500
nM, to block action potentials) and picrotoxin (50 μM, to block GABAA –mediated
currents) to isolate mEPSCs. After the 2 minute baseline recordings, the AMPA
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receptor blocker, CNQX (10 μM), was perfused into the recording chamber for 2
minutes to allow for its action. Once the CNQX was washed in for 5 minutes,
mEPSCs were recorded for 5 minutes, followed by a 10 minute wash-out of
CNQX, and then recorded from again to get a post-CNQX recording. This was
done on 2 separate cultures for a total of 5 cells.
Here we show that all mEPSCs we recorded are AMPAergic. When
mEPSCs were recorded in the presence of CNQX, all activity was silenced
(Figure 6, middle), and activity was re-established upon removal of the AMPAR
block (Figure 6, bottom). The same result was observed in 5 out of 5 cells.

III. SPECIFIC AIMS

Three Specific Aims were tested to elucidate the role of Rab3A in regulating
homeostatic synaptic plasticity:
1. Complete loss (Rab3A-/-) and mutation of Rab3A (Rab3Aebd/ebd) eliminates
the homeostatic increase in synaptic strength in dissociated mouse
cortical neuron cultures.
2. GluR2-containing AMPA receptors, not GluR1, are increased after chronic
TTX blockade, and ablation of Rab3A prevents this increase.
3. Neuronal Rab3A, not glial Rab3A, is responsible for regulating the
homeostatic increase in mEPSC amplitude.
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Specific Aim 1: Complete loss (Rab3A-/-) or mutation of Rab3A
(Rab3Aebd/ebd) eliminates the homeostatic increase in synaptic strength in
dissociated mouse cortical neuron cultures.

Rationale
As mentioned earlier, the presynaptic GTPase, Rab3A, has been
implicated in several forms of synaptic plasticity in the nervous system (Castillo
et al., 1997; Thakker-Varia et al., 2001; Wang et al., 2011). Our lab has recently
demonstrated that normally functioning Rab3A is necessary for homeostatic
synaptic plasticity at the mouse neuromuscular junction (NMJ) and that complete
loss of Rab3A results in a blunted homeostatic response to chronic activity
silencing via TTX (Wang et al., 2011). Additionally, the homeostatic increase in
synaptic strength observed at the mouse NMJ is not accompanied by an
increase surface expression of postsynaptic receptors (Wang et al., 2011) as has
been observed in many studies of homeostatic plasticity at central synapses
(Table 1). Taken together, the lack of change in postsynaptic receptor
expression, and that the requirement for a presynaptic protein, Rab3A, in
homeostatically-induced increases in synaptic strength at the mouse NMJ,
suggest that there may be a presynaptic mechanism involved in the regulation of
the activity-dependent increase in miniature endplate currents (mEPCs). One
study has provided evidence for presynaptic modulation of miniature inhibitory
postsynaptic currents (mIPSCs) in a homeostatic manner. In conjunction with
everything discussed thus far involving excitatory synaptic homeostasis,
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chronically blocking synaptic activity also triggers a decrease in the amount of
inhibition by reducing mIPSC amplitude. This has been shown to be
accompanied by a reduction in the amount of postsynaptic GABAA receptors in
neocortical synapses (Kilman et al., 2002), and by also decreasing presynaptic
vesicle filling of GABA via the reduction of the GABA biosynthetic enzyme
glutamic acid decarboxylase (GAD65) and the vesicular GABA transporter
(VGAT) in hippocampal synapses (Hartman et al., 2006). No presynaptic
regulatory role or molecule has been established for the homeostatic regulation
of excitatory synapses. Since our lab has previously shown that the Rab3A ebd/ebd
mutant impairs homeostatic synaptic plasticity at the mouse NMJ, we
hypothesized that normally functioning Rab3A is required for the homeostatic
increase in synaptic strength at central synapses.

Protocol
To test our hypothesis, we used whole-cell voltage clamp to record
mEPSCs from cortical pyramidal neurons in control and TTX-treated sister
cultures. Culture, electrophysiology, and data analysis were performed as
described earlier in the Materials and Methods section. TTX effects on cortical
pyramidal neuron mEPSC characteristics were examined on cultures prepared
from Rab3Aebd/ebd mice and compared to cultures prepared from wild-type mice in
that colony; the same comparison was performed on cultures prepared from
Rab3A-/- cortical pyramidal neurons and cultures prepared from wild-type mice in
the same colony. Rab3Aebd/ebd and Rab3A-/- mice were maintained through
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distinct, non-overlapping breeding colonies. Statistical significance was
determined as p < 0.05.

Results
To test the effect of chronic inactivity and the role of the Rab3A ebd
mutation on the physiological properties of excitatory synapses, we measured
the amplitude and frequency of mEPSCs from TTX-treated (48 hours) and
untreated sister cultures of Rab3Aebd/ebd dissociated cortical pyramidal neurons
and compared these to wild-type (Rab3A+/+) cultures. Untreated Rab3A+/+
neurons had an average amplitude of 11.0 ± 0.6 pA and occurred at a frequency
of 1.15 ± 0.19 Hz (n = 20 cells). The amplitude of mEPSCs was significantly
increased with chronic silencing of synaptic activity by TTX in Rab3A+/+ neurons
(15.1 ± 1.2, n = 23 cells, p = .007 compared to control; Figure 7A left panel, C
left, and D), and the TTX effect was blocked in Rab3Aebd/ebd cultures (untreated,
14.9 ± 1.0 pA vs. TTX-treated 14.6 ± 1.1 pA, p = 0.86. Control n = 22 cells, TTX
n = 22; Figure 7A right panel, C right, and D). We did observe that the control
mEPSC amplitude of Rab3Aebd/ebd cultures was increased (14.9 pA) when
compared to the control amplitude of Rab3A+/+ cultures (11.0 pA) and that this
increase resembled the amplitude of TTX-treated Rab3A+/+ cultures (15.1 pA)
(Figure 7D). We cannot rule out that the ebd mutation itself produces a TTX-like
effect on mEPSC amplitude that obscures the actual TTX-induction of increasing
amplitude by achieving maximal synaptic efficacy without TTX, and a similar
increase was observed at the NMJ (Wang et al., 2011). However, this may also
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be due to culture-to-culture variations in mEPSC amplitude because other labs
have shown high variability of mEPSC amplitudes across cultures (Cingolani and
Goda, 2008; Gainey et al., 2009; Stellwagen and Malenka, 2006), and we have
also seen this high variability in mEPSC amplitudes in our experiments.
Although it is possible that there exist a threshold where basal amplitude is too
large that it is no longer able to produce a homeostatic increase, we have data
and results from our pooled Rab3A+/+ cultures (Rab3A KO colony) that show TTX
treatment is able to increase mEPSC amplitude to 18.2 pA (Figure 8D); this
allows us to believe that the lack of effect of TTX to reflect true inhibition of the
homeostatic plasticity mechanism.
The mEPSC frequency of neurons from Rab3A+/+ mice also increased
significantly with chronic TTX treatment (untreated, 1.15 ± 0.19 Hz vs. TTXtreated, 2.54 ± 0.55 Hz. Untreated n = 20, TTX-treated n = 23, p = 0.030; Figure
7A left and B), which was blunted in Rab3Aebd/ebd neurons (untreated, 1.64 ± 0.39
Hz vs. TTX-treated, 3.05 ± 0.80 Hz, p = 0.12. Untreated n = 22 neurons, TTX n =
22 neurons; Figure 7A right panel and B). These results demonstrate that
normally functioning Rab3A is essential for the homeostatic increase in mEPSC
amplitude and frequency.
We next wanted to determine the effect of complete loss of Rab3A
(Rab3A-/-) on the homeostatic changes on mEPSC physiological characteristics.
To test this, we performed the same experiments as done on Rab3A ebd/ebd
neurons, but using cortical cultures from Rab3A-/- mice and their wild-type
counterparts. Untreated neurons from Rab3A+/+ exhibited a significant increase
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in both mEPSC amplitude and frequency when compared to sister cultures that
were chronically silenced for 2 days by TTX (14.0 ± 0.7 pA vs. 18.2 ± 0.8 pA, P =
0.0004, and 2.03 ± Hz vs. 4.14 ± 0.67 Hz, P = .005, respectively. Untreated n =
26, TTX n = 20; Figure 8). When the same experiments were performed on
Rab3A-/- neurons, the TTX-induced increase in mEPSC amplitude was blocked
(13.5 ± 0.8 pA vs. 14.3 ± 0.7 pA, P = 0.5, control n = 22, TTX n = 21; Figure 7A,
C, and D). Ablation of Rab3A also blunted the homeostatic increase in mEPSC
frequency (2.94 ± 0.54Hz vs 3.70 ± 1.13 Hz, P = 0.5, control n = 22, TTX n = 21;
Figure 7A and B). These results strongly suggest that Rab3A is necessary for
the physiological expression of increased synaptic strength as a result of chronic
TTX induced homeostatic synaptic plasticity in mouse cortical neurons.

Discussion
Chronic perturbations in the synaptic activity of neuronal networks are
known to cause global compensatory changes in synaptic strength between
neurons. Our findings here demonstrate the essential role of a presynaptic
protein, Rab3A, in regulating the homeostatic increase in synaptic strength at
AMPAergic synapses. Our data demonstrate that either a mutation to obstruct
Rab3A’s GTPase activity or complete loss of the protein inhibits the homeostatic
increase in mEPSC amplitude and blunts the response on mEPSC frequency in
dissociated mouse cortical pyramidal neurons.
It is well-established that chronic silencing of neuronal networks leads to
an increase in mEPSC amplitude and several molecules have been identified to

28

support the mechanism of homeostatic postsynaptic modulation of glutamatergic
AMPA receptors, including glial release of the pro-inflammatory cytokine, TNFα,
which increases expression of surface AMPARs (Beattie et al., 2002), upregulation of all-trans retinoic acid (RA) synthesis to increase surface GluR1containing AMPA receptors (Aoto et al., 2008) and the requirement of Fragile X
mental retardation protein (FMRP) in the RA-dependent upregulation of GluR1
AMPARs (Soden and Chen, 2010), loss of Arc, an immediate-early gene
associated with information encoding in the brain, results in increased basal
GluR1 surface expression and mEPSC amplitude and prevents the TTX-induced
increase in amplitude (Shepherd et al., 2006), and β3-integrin, a cell adhesion
molecule involved in the endocytosis of AMPARs, is necessary for the
homeostatic increase in cell membrane GluR2-containing AMPA receptor
numbers (Cingolani et al., 2008).
As mentioned previously, glial release of factors in response to chronic
activity deprivation have also been shown to be important for increasing synaptic
strength by increasing the amount of postsynaptic GluR1-containing AMPA
receptors. To this date, no known presynaptic mechanism or molecules have
been shown to be involved in the homeostatic increase in synaptic strength, but
our discovery that Rab3A is necessary for this process provides a novel
physiological role for Rab3A at central synapses and could provide the first
evidence of a presynaptic mechanism in homeostatic synaptic plasticity.
There are several potential Rab3A-dependent mechanisms for regulating
the increase in synaptic strength in neurons (Figure 9). Rab3A could work
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presynaptically by increasing the amount of glutamate loaded into synaptic
vesicles in response to chronic activity silencing, as has been seen with GABA in
inhibitory neurotransmission (Hartman et al., 2006). The increase in the amount
of transmitter being released per vesicle would subsequently activate more
postsynaptic AMPA receptors causing an increase in mEPSC amplitude.
Another potential Rab3A-dependent mechanism is that Rab3A homeostatically
controls the release of a presynaptic signaling molecule that travels across the
synaptic cleft to activate the increased insertion of postsynaptic AMPARs,
resulting in increased synaptic strength. A third potential mechanism for Rab3A
in homeostatic synaptic plasticity located in the postsynaptic cell could be that
Rab3A, known to be involved in the trafficking of vesicles, acts from its location
within the postsynaptic neuron by shuttling AMPAR-loaded vesicles to the
synapse when neuronal activity is deprived, allowing for increased synaptic
strength. The last mechanism whereby Rab3A could regulate the homeostatic
increase in synaptic strength is that Rab3A in glia, in response to persistent
activity suppression, modulates the release of a glial-derived factor, such as
TNFα, that signals to increase postsynaptic expression of AMPARs.
Due to the fact that malfunctioning of neuronal activity homeostasis has
been implicated in neurological and psychiatric diseases, determining Rab3A’s
role in regulating the enhancement of synaptic efficacy in this process would
provide a better understanding of this mechanism and molecular signals. This
better understanding could provide for new drug targets and therapies. As a first
step, we address whether loss of Rab3A prevents increased neurotransmitter
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loading in synaptic vesicles or increased postsynaptic AMPA receptors in
Specific Aim 2.

Specific Aim 2: Rab3A-/- blocks the homeostatic increase in postsynaptic
expression of surface GluR2-containing AMPA receptors in response to
chronic activity blockade.

Specific Aim 2 was designed to determine the role of Rab3A in the
mechanism of homeostatic synaptic plasticity. As mentioned previously, there
are several possibilities for the site of Rab3A’s mechanism of action in response
to chronic activity deprivation, such as: 1. acting presynaptically to alter synaptic
vesicle neurotransmitter concentration, 2. regulating the presynaptic release of a
molecule that signals to the postsynaptic neuron to increase AMPAR numbers, 3.
working in the postsynaptic neuron to control the increased trafficking of AMPA
receptors to the synapse, or 4. modulating the release of a glial-derived factor
that subsequently signals to increase AMPAR numbers in the postsynaptic
neuron. The scope of this Aim was to determine if Rab3A is involved in a
presynaptic mechanism by assessing the amount of transmitter loaded into
synaptic vesicles by using a glutamate competitive antagonist or if it is required
to induce the necessary postsynaptic manipulations to AMPAR numbers, and
more specifically, which AMPAR subunit, GluR1 or GluR2, it may be regulating.
We have partitioned Specific Aim 2 into 3 subsections to answer these questions:
A. Presynaptic Mechanism: Neurotransmitter Concentration, B. Postsynaptic
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Mechanism: GluR1-containing AMPARs, and C. Postsynaptic Mechanism:
GluR2-containing AMPARs.

A. Presynaptic Mechanism: Neurotransmitter Concentration

Is Rab3A mediating a presynaptic homeostatic mechanism? Links between
presynaptic homeostasis, BNDF, and Rab3A.
Our results demonstrating that the synaptic vesicle protein, Rab3A, is
necessary for the expression of increased synaptic strength in homeostatic
synaptic plasticity could lead to the first line of evidence of a presynaptic
mechanism and the identification of a presynaptic molecule linked to the process
of homeostatically increasing excitatory synaptic strength. As mentioned earlier,
homeostatic modulation of neurotransmitter concentration has been shown in
inhibitory synaptic transmission in hippocampal neurons. Chronic activity
blockade via TTX triggers a decrease in mIPSC amplitude due to TTX-induced
downregulation of the GABA synthesizing enzymes, glutamic acid decarboxylase
67 (GAD67) (Lau and Murthy, 2012) and GAD65 (Hartman et al., 2006), and
decreased vesicle loading of GABA has been demonstrated by increased
sensitivity to a competitive GABA antagonist (Hartman et al., 2006). This TTXdriven homeostatic decrease in inhibitory synaptic transmission is also regulated
by brain-derived neurotrophic factor (BDNF) via TrkB receptor signaling as
demonstrated by the prevention of the activity deprivation effects on GABAergic
synapses when cultures were co-treated with BDNF (Swanwick et al., 2006).
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BDNF application to hippocampal neurons has been shown to increase Rab3A
protein expression and to potentiate synaptic activity; the BDNF-induced
potentiation of synaptic activity is abolished in neurons lacking Rab3A (ThakkerVaria et al., 2001). These data illustrate BDNF’s role in modulating synaptic
activity in decreasing inhibitory synaptic transmission by reducing GABA
concentration in synaptic vesicles resulting in increased excitatory synaptic
transmission and increased synaptic strength. The fact that BDNF signaling is
able to 1.) vary the amount of the inhibitory transmitter, GABA, loaded into
vesicles in an activity-dependent manner, 2.) that Rab3A is required for a BDNFdriven potentiation of excitatory synaptic activity, and 3.) that no evidence to date
has implicated a homeostatic mechanism at excitatory synapses of modulation of
glutamate concentration in vesicles makes it reasonable to believe that BDNF
may be signaling through Rab3A to regulate the amount of glutamate loaded into
vesicles at excitatory synapses.

Is Rab3A mediating a presynaptic homeostatic mechanism? The role of Rab3A
in fusion pore kinetics.
Another possibility for Rab3A to modulate the amount of neurotransmitter
present in the synaptic cleft is by regulating synaptic vesicle exocytotic fusion
pore kinetics. Fusion pores are channels that form at the initial phase of
exocytosis sometimes resulting in full-collapse vesicle fusion and release of all
transmitter content of that vesicle, or, failure to achieve full fusion and releasing
varying amounts of transmitter into the synaptic cleft (Ales et al., 1999). In
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adrenal chromaffin cells, loss of Rab3A results in abnormally slow-rising and long
duration pre-spike feet of amperometric events, corresponding to fusion of single
catecholamine-containing vesicles (Wang et al., 2008). As pre-spike feet are a
measure of fusion pore dynamics (Wightman et al., 1995), this result suggests
Rab3A may regulate the amount of transmitter available in the cleft in a fusion
pore-dependent manner.

Can a change in glutamate release result in a different mEPSC amplitude?
Variations in glutamate concentration in the synaptic cleft have been
shown to be the primary source of variability in evoked EPSC amplitude. It has
also been concluded that vesicular packets of transmitter are not able to saturate
postsynaptic receptors (Liu et al., 1999), leaving room for fluctuations in
glutamate concentration as a source of variability in mEPSC amplitudes (Wu et
al., 2007), leaving the possibility for these fluctuations in vesicular glutamate
content to contribute to a presynaptic mechanism in homeostatic plasticity.
Since Rab3A localizes to synaptic boutons and associates with vesicles, is
necessary for BDNF-induced synaptic plasticity, exhibits the ability to regulate
fusion pore kinetics, and we have now shown its requirement for the expression
of homeostatic plasticity, we hypothesized that Rab3A is required for a
homeostatic increase in the amount of neurotransmitter released into the
synaptic cleft.

Protocol
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To test our hypothesis that Rab3A is homeostatically regulating the
amount of transmitter released into the synaptic cleft, we used the compound, γD-glutamylglycine (γ-DGG), to investigate this possibility. γ-DGG is a glutamate
receptor antagonist that has a low affinity for AMPA receptors (Watkins et al.,
1990) and is a rapidly dissociating competitive antagonist of glutamate (Liu et al.,
1999), allowing for the investigation of cleft glutamate concentrations. If
variations in mEPSC amplitude are due to variations in the amount of glutamate
in the cleft, there should be an inverse correlation in the amount of γ-DGG
inhibition and the size of mEPSC amplitude. In other words, if large amplitude
mEPSCs are due to increased glutamate concentration, then these larger
amplitude mEPSCs would show decreased sensitivity to γ-DGG because the
increased glutamate in the synaptic cleft would out-compete γ-DGG for AMPA
receptor binding, and vice versa.
We used whole-cell voltage clamp to record mEPSCs from untreated and
TTX-treated (48 hours) sister cultures of Rab3A+/+ (Rab3A colony) neurons
before and after γ-DGG application. Cultures were prepared as described in the
Materials and Methods section. Electrophysiology was performed as described
earlier, except basal recordings were done for 4 minutes, followed by a 2 minute
wash-in with γ-DGG (500 μM) added to perfusate, and then a 4 minute recording
from the same neuron in the presence of γ-DGG. This was done on untreated
and TTX-treated sister cultures of Rab3A+/+ neurons and results compared
between the 2 experimental conditions.
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Neuronal mEPSC data were analyzed as described in the Materials and
Methods section. Mean percent reduction of mEPSC amplitudes for each cell in
untreated and TTX-treated conditions in response to γ-DGG were calculated,
then pooled together for each condition to obtain an overall mean percent
reduction for untreated and TTX-treated conditions, and were compared.
Statistical significance was established as p < 0.05. Also, each individual
neuron’s percent reduction was plotted against its basal average mEPSC
amplitude to determine whether any relationships exist between initial amplitude
or TTX treatment and the amount of reduction on mEPSC amplitude observed
with γ-DGG inhibition.

Results
When we compared the average amount of reduction on mEPSC
amplitudes of control and TTX-treated neurons triggered by competitive
antagonism via γ-DGG, we found there was no difference between the two
conditions (26.1 ± 3.4% reduction in control vs. 26.6 ± 4.8% in TTX-treated, p =
0.9. Control n = 12, TTX n = 9; Figure 10A.). This could be due to the lack of a
strong TTX effect on mEPSC amplitude as a result of control neuron’s exhibiting
a large basal mean amplitude prior to γ-DGG application (16.2 ± 1.0 pA vs. 18.4
± 1.4 pA, p = 0.21, control n = 12, TTX n = 9, data not shown). This could
obscure any differences we may have seen in the amount of γ-DGG inhibition
because the initial amplitudes of control and TTX-treated neurons were very
similar. To address this, we then examined each cell individually to determine if
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large amplitude neurons were less sensitive to γ-DGG inhibition and if small
amplitude cells were more sensitive to γ-DGG, and whether this was dependent
on TTX-treatment. We discovered that the percent reduction on mEPSC
amplitude was independent of initial amplitude size or of a TTX effect (Figure
10B) as we observed individual neurons which had small mEPSC amplitudes
and were relatively insensitive to γ-DGG (Figure 10B and C, top, note, the
smallest amplitudes were all from untreated cultures), an untreated neuron with a
large mEPSC amplitude was highly sensitive to γ-DGG (Figure 10B and C,
middle), and a TTX-treated neuron with a large mEPSC amplitude was highly
sensitive (Figure 10B and C, bottom). These surprising results that larger
amplitudes are more sensitive to γ-DGG is opposite of what would be expected if
large mEPSC amplitude was a result of increased neurotransmitter. This
strongly suggests that the amount of γ-DGG inhibition is irrespective of mEPSC
amplitude or chronic TTX treatment.

Discussion
Our surprising results that γ-DGG was less effective in inhibiting small
amplitudes and had varying effects on mEPSC inhibition regardless of mEPSC
size or TTX effect (Figure 10B and C) strongly suggests that sensitivity to γ-DGG
is independent of amplitude and chronic network silencing. This is the opposite
result expected if variations in mEPSC amplitude were due to transmitter
concentration. If transmitter concentration was equivalent in small and large
amplitude cells, we would expect to see the same amount of reduction of
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mEPSC amplitudes of untreated and TTX-treated neurons. Instead, our results
indicate that, 1.) very large amplitude must be due to increased receptors and not
transmitter concentration, and, 2.) when increased receptors are present they
may serve as a sink for glutamate, lowering its concentration in the synaptic cleft
and making the neuron more sensitive to γ-DGG.
These results are strong evidence that presynaptic modulation of
neurotransmitter is not the mechanism for homeostatic increases in mEPSC
amplitude in the face of chronic network silencing. They also strongly suggest
that neurotransmitter concentration within synaptic vesicles is widely varying,
potentially contributing to the high variability seen in mEPSC amplitudes. Also,
neurons with large mean amplitudes actually appear to be contacted by
presynaptic neurons that have, on average, vesicles with less neurotransmitter
content because some of the largest amplitude cells exhibited the most
sensitivity to competitive antagonism by γ-DGG (Figure 10B). This heightened
sensitivity to γ-DGG in large amplitude neurons may also provide evidence for an
increase in postsynaptic AMPA receptors, which has been well-established to
contribute to activity-dependent increases in mEPSC amplitude. Our results
presented here argue against an involvement of a presynaptic mechanism
modulating an increase in neurotransmitter concentration to enhance synaptic
efficacy in response to chronic activity deprivation, and may point towards the
postsynaptic mechanism of modulating AMPA receptors and Rab3A’s
involvement in regulating their activity-dependent increase.
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B. Postsynaptic Mechanism: GluR1-containing AMPA Receptors

Rationale
Bidirectional AMPA receptor trafficking via vesicles to and from the
synapse has been well documented and occurs in an experience-dependent
manner to influence synaptic strength (Heynen et al., 2000; Takahashi et al.,
2003), and during homeostatic synaptic plasticity (Wierenga et al., 2005).
Knockout of the GluR1 subunit impairs the regulation of synaptic strength and
distance-dependent synaptic scaling in the CA1 region of the mouse
hippocampus (Andrasfalvy et al., 2003). Since AMPA receptors are known to be
shuttled to and from the cell surface and Rab3A has long been known as a small
GTPase that cycles between association and dissociation with GTP and synaptic
vesicles (Fischer von Mollard et al., 1990) to traffic vesicular cargo for exocytosis
(Matteoli et al., 1991), it is reasonable to believe that Rab3A could also be
involved in the postsynaptic transport of AMPA receptor-loaded vesicles.
As mentioned previously, modifications to postsynaptic AMPA receptor
levels are now known to play an essential role for the expression of homeostatic
synaptic plasticity, but there is disagreement between the involvement of the
GluR1 subunit or the GluR2 subunit. Several studies have demonstrated the
increased insertion of GluR1-containing AMPA receptors in response to chronic
activity blockade (Table 1). Another study showed that BDNF contributes to the
bidirectional cell surface expression of both GluR1-containing AMPA receptors
and GluR2-containing AMPA receptors in nucleus accumbens medium spiny
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neurons (Reimers et al., 2014), and 2 other studies, 1 on nucleus accumbens
neurons (Sun and Wolf, 2009) and the other on visual cortical cultures (Wierenga
et al., 2005), also showed that prolonged activity silencing increases cell surface
expression of both GluR1 and GluR2. Preferential homeostatic upregulation of
GluR2-containing AMPA receptors has also been shown (Cingolani et al., 2008)
and the GluR2 subunit has been demonstrated to be required for synaptic
scaling, a type of homeostatic plasticity (Gainey et al., 2009). Despite the
discrepancy in which AMPA receptor subunit is responsible for the expression of
homeostatic plasticity, the majority of evidence supports the upregulation of the
GluR1 subunit after prolonged activity deprivation (Table 1).
Based on our results here demonstrating Rab3A’s requirement for the
expression of increased mEPCS amplitude in homeostatic synaptic plasticity
(Figure 7 and 8) and that increased transmitter concentration does not account
for this increase in amplitude (Figure 10), we hypothesized that Rab3A is
regulating the increase in synaptic efficacy in response to chronic activity
silencing by modulating the increase in postsynaptic AMPA receptors, specifically
the GluR1 subtype since overwhelming evidence has shown the homeostatic
increase in GluR1 expression. Although we know of no postsynaptic
involvement of Rab3A in the trafficking vesicles to the membrane, it is
reasonable to believe that Rab3A could be involved in this process due to its
already known role in trafficking synaptic vesicles for exocytosis and in the
secretory pathway. The fact that BDNF-induced plasticity is reliant on Rab3A
and BDNF has recently been shown to adjust surface AMPA receptor levels in a
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homeostatic manner, allows for the possibility that Rab3A is affecting
postsynaptic AMPA receptor expression in an activity-dependent manner to
increase synaptic strength, or provides a link between Rab3A and receptor
trafficking. A potential role for Rab3A to modulate receptor trafficking could be by
regulating the release of a neuronal factor, such as BDNF, which in turn
regulates receptors postsynaptically. To our knowledge, this would provide a
novel role for Rab3A and the first evidence of its postsynaptic function.

Protocol
Here, we tested whether GluR1 is increased homeostatically using 2
approaches: 1.) immunohistochemistry of surface GluR1 expression, and 2.) a
selective GluR1 antagonist, NASPM (a synthetic analog of Joro spider toxin).
We examined GluR1 receptor levels in untreated and TTX-treated (2 days) sister
cultures, and some of these cultures we also measured mEPSC amplitudes to
establish a physiological correlate with the staining for GluR1 expression.
NASPM experiments were performed on untreated and TTX-treated (2 days)
sister cultures and all recordings were done before and after NASPM.

Immunohistochemistry.
Primary cultures of wild-type mouse cortical neurons and TTX treatment
were prepared as described in the Materials and Methods section. Surface
expression of GluR1 was examined on 2 week old cultures of untreated and
TTX-treated sister cultures of wild-type pyramidal neurons. Antibody to GluR1
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(see Table 2 for information regarding antibodies) was added to unfixed
coverslips in the culture media in which each coverslip was grown (so not to
introduce any changes in osmolarity or factors released by glia and neurons that
coverslips have been exposed to while in culture), 5% donkey serum. Coverslips
were incubated for 45 minutes in a 37°C, 5% CO2 incubator. Neurons were then
rinsed with PBS, fixed for 10 minutes in 4% paraformaldehyde at room
temperature, rinsed with PBS, and then rinsed with donkey serum, and incubated
1 hour at room temperature with Cy5 (649) donkey anti-rabbit secondary
antibody (Jackson Immunoresearch) in 5% donkey serum. The cells were then
permeabilized with 0.2% saponin before incubating in MAP2 and VGLUT1
antibodies, to label cell bodies and dendrites, and presynaptic glutamatergic
terminals, respectively. Cells were then incubated in secondary antibodies for 45
minutes, rinsed, and then mounted to slides using VectaShield mounting medium
(Vector Labs) to reduce photobleaching. Slides were stored at 4°C and imaged
within a few days by confocal microscopy.
Confocal images were acquired on an Olympus FV1000 confocal
microscope using FluoView 2.1 software. The objective was 60X (oil immersion),
with a numerical aperture of 1.35. A single image of a visually identified
pyramidal neuron was acquired before applying a 5X zoom to acquire a stack of
images of the primary dendrite (section thickness = 0.5 microns). Where
possible, ten cells and their primary dendrites were imaged per coverslip per
treatment condition (untreated and TTX-treated). Imaging parameters of PMT
and laser percent were adjusted for each laser to maximize brightness without
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causing saturation. The same parameters were used for untreated and TTXtreated coverslips from a single experiment.

Image Analysis
The confocal z-stack of the dendrite was flattened using Image Pro 6
(Cybernetics), and an area of interest (AOI) defined that included the dendrite
plus a fixed amount outside the dendrite (to capture receptor clusters on spines)
that was defined by using the process command morphological filter to “swell”
the dendrite. To quantify the size, intensity, and integrated intensity of receptor
clusters, a threshold was set (400-600 depending on overall brightness; the
same threshold was used for untreated and TTX-treated in a single experiment)
and the count command applied to automatically circle receptor clusters that
were located within the AOI. To exclude multiple clusters that had been circled
as a single cluster due to their proximity, clusters larger than 0.8 microns (check
by looking at several dendrites and finding out what is the biggest size) were not
included in the analysis. Cluster area, intensity, and integrated intensity were
acquired, and the average across the clusters determined for each dendrite, and
then an overall average across dendrites were calculated. The effect of TTX was
assessed in 2 ways. For the total number of 7 experiments, the untreated and
TTX-treated means for each experiment were compared with a student’s t-Test,
where n = number of experiments. For 2 experiments in which physiology was
performed on the same day as immunohistochemistry, data are presented as
individual experiments.
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Synaptic Analysis
In ImagePro 6, dendrite (color 1), VGLUT1-positive presynaptic terminal
(color 2) and receptor antibody-positve clusters (color 3) are visible
simultaneously in the composite image, facilitating identification of synaptic pairs
that are located on or close to the dendrite. To find a synaptic pair, the slice
number is cycled up and down the confocal stack, and coexisting pre- and
postsynaptic sites circled by hand to create the AOIs. The stack number for each
AOI is noted for use later. When all of the synaptic pairs for an individual dendrite
have been circled, the AOI list is saved. Next, the single color image for
receptors is viewed, each AOI is placed on the image, on the correct confocal
slice, and the count tool is used to automatically circle the receptor cluster. The
measurement values (area, intensity, and sum) are copied to an Origin file, with
all of the data for a single dendrite accumulated in one worksheet, for calculating
an average for the dendrite.

Physiological Blockade of GluR1-mediated mEPSCs by NASPM
N-naphthyl acetylspermine (NASPM) is a selective antagonist of GluR2lacking AMPA receptors (Koike et al., 1997). It has been shown to abolish
homeostatic induced increases in mEPSC amplitudes induced in chick
motoneurons in vivo by activity blockade via the sodium channel blocker,
lidocaine, for 2 days (Garcia-Bereguiain et al., 2013), which suggests that in that
preparation GluR2-lacking AMPA receptors are entirely responsible for the
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activity-deprivation induced increase in mEPSC amplitude. Cultures were
prepared and whole-cell voltage clamp was performed as described in the
Materials and Methods section. Baseline recordings were performed for 2
minutes and the same patched cell was then perfused with a high K+ solution
containing NASPM (same solution used for baseline recordings except [KCl] = 25
mM, [NaCl] = 95 mM, and NASPM = 20 μM) for 45 seconds. NASPM is an
activity-dependent drug, so perfusion with the high K+ solution caused the cell to
depolarize, inducing a high frequency of evoked synaptic events (personal
observation) which allows glutamate binding to open GluR2-lacking AMPA
receptors. After 45 seconds, perfusion was returned to our normal extracellular
solution used for the basal recordings, but with NASPM (20 μM) and the cell was
allowed to recover its membrane potential to resting levels. After 5 minutes, a 5
minute recording of mEPSCs was then acquired in the presence of NASPM. For
each cell, there was a baseline recording and a NASPM recording.
Mean pre-NASPM recordings for each cell in each condition (untreated vs.
TTX-treated) were pooled together to acquire an overall mean amplitude and
frequency for untreated and TTX-treated conditions. These were then compared
to determine a TTX effect on mEPSC amplitude and frequency. NASPM’s effect
on mEPSC amplitude and frequency was determined by comparing the different
conditions, untreated vs. TTX-treated, before and after NASPM. TTX effects on
mEPSC characteristics was established by an unpaired Student’s t-test
comparing overall means of untreated and TTX-treated pre-NASPM recordings,
and NASPM’s effect on each neuron’s mEPSC amplitude and frequency was
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compared before and after NASPM using a paired sample t-test. Statistical
significance was determined as p < 0.05. In addition, we calculated the mean
amplitude for the largest 25 events from each neuron recorded from and plotted
the percent change in amplitude after NASPM against the pre-NASPM amplitude
for each individual neuron.

Results

Effect of activity blockade on GluR1 receptor levels: immunohistochemistry
We stained untreated and TTX-treated Rab3A+/+ cultures for GluR1 to
determine if the homeostatic increase in mEPSC amplitude seen with chronic
activity silencing is accompanied by an increase in cell surface expression of
GluR1-containing AMPA receptors. Example images of GluR1 expression in
untreated and TTX-treated cultures are shown in Figure 11 (these images are
only intended to demonstrate immunohistochemistry of MAP2, VGLUT1, and
GluR1 expression; not to show any differences between untreated and TTXtreated conditions). We found that overall total size of GluR1 puncta did not
change between control and TTX-treated sister cultures of Rab3A+/+ pyramidal
neurons (0.32 ± 0.06 μm2 vs. 0.31 ± 0.05 μm2, paired t-Test p = 0.9, n = 7
cultures; Figure 12A, left). There was also no difference GluR1 cluster intensity
in untreated and TTX-treated Rab3A+/+ cultures (untreated, 988 ± 51 arbitrary
units (a.u.) vs. 991 ± 56 a.u., paired t-Test p = 0.8, n = 7 cultures; Figure 12B,
left). When we analyzed individual experiments, we found a variable effect of
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chronic TTX silencing on GluR1 size in Rab3A+/+; out of 7 cultures, 2 showed a
dramatic increase in GluR1 puncta size (60% and 78%; Figure 12A, right), 1
showed a decrease (-53%, Figure 12A, right), and 4 showed very modest
changes (12%, -10%, -14%, and -16%; Figure 12A, right). Analysis of individual
experiments on surface GluR1 intensity showed there were essentially little to no
change in intensity (Figure 12B, right). These results left us with the questions of
whether there are multiple mechanisms involved in the expression of
homeostatic synaptic plasticity as has been suggested by the disagreement over
GluR1 or GluR2 involvement (see Table 1, addressed in Specific Aim 2C), or,
sometimes there is not a TTX effect on mEPSC amplitude (addressed below).
Because we have seen some individual wild-type cultures that have not
exhibited a measurable physiological increase in mEPSC amplitude after TTX
blockade, and the differences in GluR1 immunohistochemistry from experiment
to experiment varied widely (Figure 12A, right), we examined GluR1
immunohistochemistry in 2 cultures for which we also performed
electrophysiological measurements on the same day. Recordings were taken
from neurons in untreated and TTX-treated cultures and coverslips from the
same cultures were subjected to immunohistochemistry for surface GluR1
expression; this would allow us to determine a correlation between a
physiological TTX-induced increase in mEPSC amplitude and cell surface GluR1
expression. To our knowledge, recordings of mEPSCs from the same cultures
that are used investigate AMPA receptor expression by immunohistochemistry
have never been done before. For imaging and GluR1 immunohistochemistry
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analysis, we presented all dendrites imaged from each of the 2 experiments
along with the mean across dendrites for each experiment. We also added an
analysis of synaptically identified GluR1 clusters, selected by their proximity to
presynaptic VGLUT1.
In the first physiology-GluR1 immunohistochemistry correlation experiment
(Experiment 1), we observed an increase in mEPSC amplitude after chronic TTX
treatment, that did not reach significance (untreated, 13.8 ± 2.2 pA vs. TTXtreated, 17.7 ± 1.8 pA, p = 0.19. Untreated n = 7, TTX treated n = 8 neurons;
Figure 13A). Because the TTX effect is of small magnitude, the number of cells
needed to observe a statistically significant effect is usually >8, which is why we
perform multiple days of recordings. Despite this caveat, Experiment 1 showed a
strong trend towards a TTX-induced increase in mEPSC amplitude that we felt
would be accompanied by at least a trend toward increased surface GluR1
expression after chronic TTX-treatment if GluR1 were the AMPA receptor subunit
responsible for the homeostatic increase in mEPSC amplitude. The results were
clear; there was no change in total GluR1 puncta size after chronic silencing
(untreated, 0.28 ± 0.02 μm2 vs. TTX-treated, 0.27 ± 0.02 μm2, p = 0.87.
Untreated n = 10, TTX-treated n = 9; Figure 13B, left) or in total GluR1 intensity
(untreated, 741 ± 19 a.u. vs. 738 ± 5 a.u., p = 0.86. Untreated n = 10, TTXtreated n = 9; Figure 13B, right), and the same result was seen with synaptic
GluR1 cluster size (untreated, 0.15 ± 0.02 μm2 vs. TTX-treated, 0.17 ± 0.02 μm2,
p = 0.44. Untreated n = 10, TTX-treated n = 10; Figure 13C, left) and synaptic
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GluR1 intensity (untreated, 657 ± 22 μm2 vs. TTX-treated, 663 ± 17 μm2, p =
0.83. Untreated n = 10, TTX-treated n = 10; Figure 13C, right).
The second time we performed the physiology-GluR1
immunohistochemistry experiment (Experiment 2), we had a strong TTX-induced
increase in mEPSC amplitude (untreated, 13.5 ± 1.5 pA vs. TTX-treated, 19.1 ±
1.8 pA, p = 0.034. Untreated n = 7, TTX-treated n = 6; Figure 14A). Because of
the strong TTX effect on mEPSC amplitude in Experiment 2, we would expect a
very clear increase in GluR1 expression if GluR1 upregulation were mediating
the homeostatic increase mEPSC amplitude. Again, the results were clear;
surface GluR1 expression in Experiment 2 did not increase (puncta size:
untreated, 0.27 ± 0.04 μm2 vs. TTX-treated, 0.22 ± 0.01 μm2, p = 0.18; Figure
14B, left. Intensity: untreated, 761 ± 17 a.u. vs. TTX-treated, 750 ± 8 μm2, p =
0.58; Figure 14B, right. Untreated n = 10, TTX-treated n = 10). There were also
no homeostatic changes in synaptic GluR1 expression (puncta size: untreated,
0.13 ± 0.01 μm2 vs. 0.13 ± 0.02 μm2, p = 0.83; Figure 14C, left. Intensity: 615 ±
13 a.u. vs. 631 ± 17 a.u., p = 0.45; Figure 14C, right. Untreated n = 10, TTXtreated n = 10).
In summary, when physiology-GluR1 expression correlation experiments
were performed, we found no evidence of an increase in GluR1 levels, despite
there being a clear demonstration of a TTX-induced increase in mEPSC
amplitude in the same experiment. These results suggest that either GluR1 is
not involved in the homeostatic response to chronic activity deprivation, which is

49

unlikely due to the prevalence of studies showing GluR1 increased
homeostatically, or there multiple homeostatic mechanisms exist.
We also performed immunohistochemistry experiments for GluR1
expression in response to chronic TTX treatment in Rab3A-/- cultures.
Interestingly, there was a modest homeostatic increase in GluR1 levels despite
the loss of Rab3A (untreated, 0.30 ± 0.03 μm2 vs. TTX-treated, 0.33 ± 0.03 μm2,
p = 0.40, n = 7 cultures; Figure 15A), and analysis of individual cultures revealed
that 2 out of 4 experiments demonstrated the modest homeostatic increase in
GluR1 puncta size (Figure 15B). These data from Rab3A-/-, like the
immunohistochemistry experiments examining homeostatic changes in GluR1
levels in wild-type cultures, again show that a subset of cultures show a modest
homeostatic increase in GluR1 expression, and that loss of Rab3A does not
prevent this increase.

Effect of activity blockade on GluR1 levels: selective antagonism by NASPM
Because immunohistochemistry experiments revealed no changes in
GluR1 levels after chronic TTX-treatment even when a homeostatic increase in
mEPSC was observed (Figures 13 and 14), it is possible that
immunohistochemistry was not sensitive enough, that our methods of analysis
failed to pick up a genuine change, or multiple mechanisms can increase
mEPSC amplitude in a homeostatic manner. Since several other studies have
shown increased GluR1 levels after chronic activity silencing (Table 1), we used
another independent measure that should reveal if there were a significant
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increase in GluR1 homomers, a selective antagonist of GluR2-lacking receptors
that has previously been used to demonstrate a selective contribution of GluR2lacking receptors to a homeostatic increase in synaptic strength in chick spinal
cord neurons (Garcia-Bereguiain et al., 2013). If the increase in synaptic
strength after chronic activity-deprivation is due to increased expression of GluR1
homomeric receptors, we would expect NASPM application to abolish the
increase in mEPSC amplitudes in TTX-treated neurons. The most striking effect
of NASPM we found was on mEPSC frequency. We were surprised to find that
the homeostatic increase in mEPSC frequency (untreated pre-NASPM, 1.88 ±
0.41 Hz vs. TTX-treated pre-NASPM, 4.23 ± 0.90 Hz, untreated n = 16 neurons,
TTX n = 13 neurons, p = 0.017; Figure 16C) was abolished after NASPM
(untreated pre-NASPM, 1.88 ± 0.41Hz vs. TTX-treated NASPM, 2.40 ± 0.61,
untreated n = 16 neurons, TTX n = 13 neurons, p = 0.47; Figure 16C). Paired
analysis before and after NASPM for both untreated and TTX-treated conditions
showed significant decreases in mEPSC frequency in response to NASPM
inhibition, although the effect was more pronounced in TTX-treated cultures
(untreated: pre-NASPM, 1.88 ± 0.41 Hz vs. NASPM, 1.46 ± 0.36 Hz, n = 16, p =
0.027; Figure 16C, black bars. TTX-treated: pre-NASPM, 4.23 ± 0.90 Hz vs.
NASPM, 2.40 ± 0.61 Hz, n = 13, p = 0.006; Figure 16C, green bars, and E).
Our result showing that NASPM inhibition of GluR1 AMPA receptors
blocks the homeostatic increase in frequency is highlighted in an individual
neuron from a TTX-treated culture in Figure 16. Figure 16D shows a portion of a
recording before and after NASPM where the frequency was decreased by
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43.4%, but there was no effect of NASPM on decreasing that same cell’s
mEPSC amplitude (pre-NASPM, 18.6 pA vs. NASPM, 18.9 pA; Figure 16B, right
- the histogram plot in Figure 16B labeled “Neuron 2” is from the same cell as the
example trace in Figure 16D). If GluR1-containing AMPA receptors were solely
responsible for the homeostatic increase in amplitude, we would have expected
this cell, which exhibited a TTX-induced increase in mean amplitude (18.6 pA), to
have a mean amplitude after NASPM (18.9 pA) that resembled the mean
amplitude of untreated cultures (~ 13 pA). Our findings that inhibition of GluR1containing AMPA receptors via NASPM has varying effects on blocking the TTXinduced increase in mEPSC amplitude but does block the homeostatic increase
in frequency, suggests that postsynaptic patches of AMPA receptors are not
heterogeneous mixtures of different receptor subunits, but rather are exclusively
regions of either GluR1-containing or GluR2-containing receptors. To our
knowledge, this is a novel finding.
Whole-cell voltage clamp of pyramidal neurons from Rab3A+/+ cultures
showed an increase in mEPSC amplitude in response to chronic TTX-treatment
when pre-NASPM recordings from untreated and TTX-treated (48 hours) were
compared (untreated, 13.1 ± 0.9 pA vs. TTX, 16.6 ± 1.0 pA, p = 0.016, 26.7%
increase in amplitude. Untreated n = 16 cells, TTX-treated n = 13 cells; Figure
16A). However, NASPM treatment did not affect the TTX-induced increase in
amplitude (untreated to TTX-treated % increase after NASPM = 26.6%), and they
did not resemble untreated, pre-NASPM recordings as would be expected if the
homeostatic increase in mEPSC amplitude were due to increased GluR1
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expression (untreated pre-NASPM, 13.1 ± 0.9 pA vs. TTX NASPM, 15.7 ± 0.9
pA, p = 0.06. Untreated pre-NASPM n = 16, TTX-treated NASPM n = 13; Figure
16A, CON pre bar vs. TTX NASPM bar).
These results are unlikely to be due to a lack of effect of NASPM because
paired analysis of individual neurons showed very slight, but not significant,
reductions in mEPSC amplitude after NASPM (untreated pre-NASPM 13.1 ± 0.9
pA vs. untreated NASPM 12.4 ± 0.7 pA, p = 0.29, n = 16; Figure 16A, black bars.
TTX-treated pre-NASPM 16.6 ± 1.0 pA vs. TTX-treated NASPM 15.7 ± 0.9 pA, n
= 13, p = 0.18; Figure 16A, green bars). In addition, we observed a clear and
consistent effect of NASPM on frequency, regardless of its effect on amplitude
(Figure 16C)
Further examination of the amplitude histograms in cells in which NASPM
caused a reduction in amplitude, suggests that NASPM may be mainly acting on
the largest amplitude events (Figure 16B, Neuron 1, compare pre and post
NASPM). To examine whether NASPM had a differential effect on the largest
amplitude events, we determined the mean of the top 25 events, before and after
NASPM, and calculated a percent change. While there was not a significant
difference in magnitude of NASPM effect in untreated and TTX-treated cells,
when we plotted the percent change as a function of the pre-NASPM mean of the
largest 25 events in each cell, there was a weak (R2 = 0.19) but significant (p =
0.01) relationship, with the cells that had the largest “top 25” means having the
largest decreases with NASPM. Since the cells with the largest “top 25” means
are TTX-treated cells, this result suggests there is some contribution, albeit
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small, of Glur2-lacking receptors to the TTX-induced increase in mEPSC
amplitude in our cultures.

Discussion
Our evidence of neurons with larger events trending to towards increased
NASPM sensitivity, coupled with the result that 2 out of 7 of the GluR1
immunohistochemistry experiments on wild-type cultures and 2 out of 4
experiments on Rab3A-/- cultures showed a homeostatic increase in GluR1
expression, points toward some involvement of GluR1 in homeostatic plasticity
that is not Rab3A-dependent in our cultures, but clearly cannot fully explain the
homeostatic increase in mEPSC amplitude. Based on these data using 2
independent approaches, immunohistochemistry and pharmacology, we
demonstrate that the TTX-induced increase in mEPSC amplitude in our
preparation is not due to a selective increase GluR1 receptor expression. It was
very surprising to us that NASPM did block the homeostatic increase in
frequency, a novel finding suggesting homogeneity of receptor type expression in
individual receptor patches.

C. Postsynaptic Mechanism: GluR2-containing AMPA Receptors

Rationale
Since our thorough approach using 2 independent methods of
immunohistochemistry and pharmacology did not expose a strong role for GluR1
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in the homeostatic increase in mEPSC amplitude (Specific Aim 2B), we wanted
to test whether an increase in GluR2-containing AMPA receptor number was
responsible for the increase in synaptic strength in our cultures, and if Rab3A
was involved in this process. Although evidence predominantly has implicated
GluR1 upregulation as the source for the homeostatic increase in mEPSC
amplitude, other labs have shown that GluR2 is responsible for the increase in
mEPSC amplitude after chronic network silencing (Table 1).

Protocol
Cultures, physiology, and immunohistochemistry experiments were
performed as described in Specific Aim 2B, with the exception that GluR2
immunohistochemistry analysis looked at synaptic GluR2 expression only due to
the extreme amount of GluR2 expression that made it impossible to ensure that
individual clusters could be automatically circled across the whole dendrite in a
flattened image. In some immunohistochemistry experiments had
electrophysiology performed on the same day. Physiology statistics were
performed as described in the Materials and Methods section and
immunohistochemistry statistics were performed as outlined in Specific Aim 2.

Results
We performed immunohistochemistry on untreated and TTX-treated sister
cultures of Rab3A+/+ and Rab3A-/- cortical pyramidal neurons to test if GluR2
expression is upregulated with chronic activity deprivation and whether loss of
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Rab3A affects GluR2 expression patterns. Example images of GluR2
immunohistochemistry are in Figure 17 (these are simply for demonstration of
synaptic sites, and not intended to show any TTX-induced changes in GluR2
expression). Chronic TTX treatment produced a modest increase in synaptic
GluR2 cluster size in pyramidal neurons from Rab3A+/+ cultures (untreated, 0.83
± 0.08 μm2 vs. TTX-treated, 0.97 ± 0.10 μm2, p = 0.18 (paired t-Test). Untreated
n = 5,TTX-treated n = 5; Figure 18A, left), and this modest effect on GluR2
expression was blocked in Rab3A-/- cultures (untreated, 0.75 ± 0.17 μm2 vs. TTXtreated, 0.74 ± 0.07 μm2, p = 0.94 (paired t-Test). Untreated n = 4, TTX-treated n
= 4; Figure 18C, left). As we observed with GluR1 expression after chronic TTX
treatment (Figure 12), homeostatic changes in GluR2 expression also had
experiment to experiment variation (Figure 18A, right, and 18C, right), although
to a lesser degree than GluR1. Interestingly, 4 out of 5 experiments on Rab3A+/+
cultures showed a homeostatic increase in synaptic GluR2 puncta size while the
other experiment showed a decrease in GluR2 puncta size (Figure 18A, right),
and 3 out of 4 experiments on Rab3A-/- cultures exhibited a decrease after TTX
while the other experiment showed a dramatic increase GluR2 expression
(Figure 18C, right). GluR2 intensity did not change in response to TTX treatment
either in Rab3A+/+ cultures (untreated, 731 ± 38 a.u. vs. TTX-treated, 735 ± 27
a.u., p = 0.77 (paired t-Test). Untreated n = 5, TTX-treated n = 5; Figure 18B) or
in Rab3A-/- cultures (untreated, 715 ± 38 a.u. vs. TTX-treated, 735 ± 14 a.u., p =
0.64 (paired t-Test). Untreated n = 4, TTX-treated n = 4; Figure 18D).
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Although these results suggest Rab3A may have some involvement in the
homeostatic upregulation of GluR2-containing AMPA receptors, the 2
experiments that had the opposite expected effects on changes in GluR2
expression after TTX was puzzling. In some of these experiments, we also
performed electrophysiology, so we wanted to determine, as we did with GluR1,
if there was a correlation between a homeostatic increase in mEPSC that was
accompanied by an increase in GluR2 expression in the same culture. Of the 5
Rab3A+/+ cultures we performed GluR2 immunohistochemistry on, we also
recorded mEPSCs in 3 experiments. In Experiment 1 (Rab3A+/+), a homeostatic
increase in mEPSC amplitude (28.3%) was observed (not significant, p = 0.19;
Figure 19A) and was accompanied by a 47.5% increase in synaptic GluR2
puncta size (not significant, p = 0.13; Figure 19B, left). Experiment 2 (Rab3A+/+)
also showed a correlation between a TTX-induced increase in mEPSC amplitude
(12.0%, not significant, p = 0.58; Figure 19C) and increased synaptic GluR2
expression after chronic silencing (20.6%, not significant, p = 0.25; Figure 19D,
left). (Note: the modest size of the homeostatic effect is such that we do not
expect individual experiments with these n’s to reach significance). The fact that
the modest increase in amplitude observed in Experiment 2 (Rab3A+/+) was
accompanied by a similarly modest increase in GluR2 expression, and that the
large homeostatic increase in mEPSC amplitude seen in Experiment 1
(Rab3A+/+) was accompanied by a large increase in GluR2 expression in
suggests that in these 2 cultures GluR2 upregulation is responsible for the
homeostatic increase in mEPSC amplitude.
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The third physiology-GluR2 immunohistochemistry experiment on
Rab3A+/+ cultures (Rab3A+/+, Experiment 3) produced a surprising result where a
17.2% homeostatic increase in amplitude (not significant, p = 0.09; Figure19E)
was accompanied by a 9.2% decrease in synaptic GluR2 puncta size (not
significant, p = 0.58; Figure 19F, left). Another study has also shown that a
homeostatic decrease in GluR2-containing AMPA receptors after chronic activity
deprivation results in increased mEPSC conductance which is mediated by a
resulting increase in the proportion of GluR1 homomers (Garcia-Bereguiain et al.,
2013), which are reported to have a larger conductance than GluR1-GluR2
(Swanson et al., 1997). Such a shift from heteromers to GluR1 homomers could
possibly explain why a modest homeostatic increase in mEPSC amplitude might
be accompanied by an decrease in GluR2.
Physiology-GluR2 immunohistochemistry correlation experiments were
also performed on cortical cultures from Rab3A-/- mice to test whether loss of
Rab3A affects the homeostatic expression of GluR2 AMPA receptors. In
Experiment 1 (Rab3A-/-), we saw a slight increase in mEPSC amplitude with
chronic TTX treatment (11.4%, not significant, p = 0.53; Figure 19G) that was
accompanied by a very large increase in GluR2 puncta size (146.8%, p = 0.0002;
Figure 19H, left). It is puzzling that this very large homeostatic increase in GluR2
expression (146.8%) was not accompanied by a correlative very large increase in
mEPSC amplitude (11.4%), but large homeostatic increases in GluR2 expression
(>140%) have been reported by other labs (Sun and Wolf, 2009; Wierenga et al.,
2005). Also, it must be noted that in Experiment 1 (Rab3-/-) the untreated GluR2
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puncta size is much smaller (Figure 19H, left) than any of the other GluR2
immunohistochemistry experiments examining puncta size, leaving us with the
question of whether there truly was a very large increase in synaptic GluR2
puncta size or if this increase was exaggerated due to the unexplained low
GluR2 expression in the untreated condition.
Experiments 2 and 3 from Rab3A-/- cultures produced similar results to
each other where the loss of Rab3A not only blocked the homeostatic increase in
mEPSC amplitude, but also caused it to decrease slightly (Experiment 2: -6.5%,
Figure 19I, left; Experiment 3: -11.2%, Figure 19K, left), and the decreases in
amplitude were accompanied by correlative decreases in synaptic GluR2 puncta
size (Experiment 2: -7.2%, Figure 19J, left; Experiment 3: -11.3%, Figure 19L,
left). The results from Experiments 2 and 3 on Rab3A-/- cultures suggest that in
these two cultures that the loss of Rab3A blocked the homeostatic increase in
GluR2 expression resulting in the inhibition of the homeostatic increase in
mEPSC amplitude.

Discussion
Our results examining the role of GluR2 expression in response to chronic
network silencing showed that in some cultures GluR2 levels are homeostatically
increased and that the loss of Rab3A appears to block their increase which
results in the inhibition of the homeostatic response on mEPSC amplitude.
However, in Experiment 3 on Rab3A+/+ cultures (Figure 19E and F), where a
homeostatic increase in mEPSC amplitude was accompanied by a decrease in
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GluR2 expression, strongly suggests that multiple mechanisms may be involved
in the expression of homeostatic synaptic plasticity, as has been suggested by
others (Garcia-Bereguiain et al., 2013) (see also Table 1).

Specific Aim 3: Neuronal Rab3A, not glial Rab3A, is responsible for
regulating the homeostatic increase in mEPSC amplitude.

Rationale
We have shown in Specific Aim 1 that Rab3A is essential for the
homeostatic increase in synaptic strength (Figures 7 and 8). As mentioned
earlier, several possibilities exist as to the location of where Rab3A may be
acting to exert its regulatory action to increase mEPSC amplitude in a
homeostatic manner (Figure 9).
Mounting evidence suggests that glial-neuronal interactions are complex
and important for normal nervous system function (Haydon, 2001). As
mentioned earlier, glia have been shown to be important for enhancing excitatory
neurotransmission by releasing factors such as glypican-4 and TNFα to increase
synaptic strength, and TNFα has been demonstrated to be essential for
homeostatic synaptic plasticity. Both of these molecules produce their effect by
increasing cell surface expressionof GluR1-containing AMPA receptors (Allen et
al., 2012; Stellwagen and Malenka, 2006). Since Rab3A is expressed in glia
(Madison et al., 1996), it is reasonable to believe that glial Rab3A may mediate
the release of activity-dependent factors, such as TNFα, from glia in response to
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activity deprivation, that signal to increase AMPA receptor insertion into the
postsynaptic membrane. The scope of Specific Aim 3 was to determine whether
neuronal or glial Rab3A was modulating the homeostatic increase in synaptic
strength.

Protocol
To test our hypothesis that glial Rab3A is necessary for the increase in
synaptic strength in homeostatic synaptic plasticity, we cultured Rab3A +/+
neurons onto Rab3A-/- or Rab3A+/+ glial feeder layers, and Rab3A-/- neurons onto
Rab3A+/+ glia (Figure 20A).

Preparation of Glial Feeder Layers
Glial feeder layers were prepared from the cortices of P0-P2 Rab3A+/+ or
Rab3A-/- mouse pups. Cortices were dissected and cells were dissociated as
described previously in the Materials and Methods section. Cell suspensions of
mixed neuronal and glial populations were plated onto glass coverslips precoated with poly-L-lysine (Corning) in Dulbecco’s Modified Eagle Media (Life
Technologies, Invitrogen) supplemented with 5% FBS (to promote glial
proliferation and to kill neurons), L-glutamine, and gentamicin, and maintained in
an incubator at 37°C, 5% CO2; cultures were maintained in this manner for up to
1 month until seeded with neurons. Culture media was replaced after 24 hours,
and subsequent media changes were made twice weekly replacing half of the
culture media with fresh media. Feeder layers were not used for neuronal
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seeding until all native neurons were gone and glial cells approached 100%
confluency (visually inspected).

Plating of Neurons on Glial Feeder Layers
Cortical neurons were obtained as described in the Materials and Methods
section. Upon acquisition of a pellet containing mixed neuronal and glial
populations, the pellet was resuspended in Neurobasal-A (270 mOsm) containing
B27 (2%, to promote neuronal growth), L-glutamine, and 5-fluorodeoxyuridine
(FdU, a mitotic inhibitor). Addition of FdU was used to prevent glial growth and
contamination of the glial feeder layer with new glia, promoting only neuronal
growth on the feeder layers (this media was used for the maintenance of these
cultures and all subsequent media changes were with this media). Glial culture
media was removed from the feeder layer cultures, and the cell suspension was
plated onto the glial feeder cultures. Culture strategy is outlined in Figure 15A.
At 1 DIV all of the culture media was removed and replaced with fresh
Neurobasal-A media described above, and half of the media was replaced twice
per week for all subsequent media changes. Cultures were maintained in a
37°C, 5% CO2 incubator for 13-14 days.

Electrophysiology
TTX treatment of cultures, whole-cell voltage clamp, data acquisition, data
analysis, and statistics of mEPSCs from cortical pyramidal neurons were
performed as described in the Materials and Methods section.
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Results
To test whether glial Rab3A was responsible for the homeostatic increase
in synaptic strength, we cultured wild-type neurons onto Rab3A-/- glial feeder
layers and recorded mEPSCs from untreated cultures and TTX-treated (48
hours) sister cultures and compared mEPSC amplitude and frequency between
the two conditions. We first performed these experiments on cultures of wildtype neurons on wild-type glial feeder layers to demonstrate that this new
culturing strategy of glial feeder layers exhibited a homeostatic increase in
mEPSC amplitude (untreated, 13.3 ± 0.5 pA vs. TTX-treated, 16.7 ± 1.2 pA, p =
0.022. Untreated n = 17, TTX-treated n = 20; Figure 20B, left and middle).
Despite not being significant, these cultures trended towards a homeostatic
increase in frequency (untreated, 2.54 ± 0.57 Hz vs. TTX-treated, 3.48 ± 0.64 Hz,
p = 0.29. Figure 20B, right) – (mEPSC data from Specific Aim 1 showing initial
results of a homeostatic increase in synaptic strength in our original culturing
strategy of wild-type neurons are provided in Figure 20C for reference).
Rab3A+/+ neurons plated on Rab3A-/- glia still showed a robust homeostatic
response on mEPSC amplitude (untreated, 13.3 ± 1.0 pA vs. TTX-treated, 18.8 ±
1.4 pA, p = 0.005. Untreated n = 11, TTX-treated n = 11; Figure 20D, left and
middle), and trended towards a homeostatic increase in frequency (untreated,
2.01 ± 0.41 Hz vs. TTX-treated, 4.47 ± 1.53 Hz, p = 0.14; Figure 20D, right). This
result indicates that Rab3A is not required in the glia. We also performed the
same experiment on cultures of Rab3A-/- neurons on wild-type glia, and the
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homeostatic response was reduced and no longer significant (untreated, 15.2 ±
1.1 pA vs. TTX-treated, 16.9 ± 0.7 pA, p = 0.23. Untreated n = 14, TTX-treated n
= 11; Figure 20E, left and middle), but there was a slight decrease in mEPSC
frequency that was not significant (untreated, 4.47 ± 1.21 Hz vs. 3.02 ± 0.70 Hz,
p = 0.35; Figure 20E, right) – (mEPSC data from Specific Aim 1 showing initial
results of loss of Rab3A blocking the homeostatic increase in synaptic strength in
our original culturing strategy are provided in Figure 20F for reference). These
results further confirm that Rab3A localized within neurons is playing a key role in
regulating homeostatic synaptic plasticity.

Discussion
These results, that loss of glial Rab3A does not block the homeostatic
increase in mEPSC amplitude, and loss of neuronal Rab3A does block the TTXinduced increase in amplitude, focuses the potential possibilities for Rab3Adependent homeostatic increases in mEPSC amplitude to two possible
mechanisms. The first possibility is that Rab3A is working in the presynaptic
neuron, not to modulate transmitter content within synaptic vesicles as we
originally postulated (see Specific Aim 2A, and Figure 10), but rather by
regulating the anterograde signaling of the presynaptic release of neurotrophic
factors that travel across the synaptic cleft that subsequently signal to increase
AMPA receptor levels in the postsynaptic membrane (Figure 9, #2). The second
possibility is that Rab3A is located in the postsynaptic neuron and is involved in
increasing the trafficking of AMPA receptors for insertion into the postsynaptic
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membrane in response to chronic activity deprivation (Figure 9, #3). Both of
these possibilities would provide new insight and better understanding of the
homeostatic mechanism for increasing mEPSC amplitude. To our knowledge,
there is currently no evidence for anterograde signaling from the presynaptic to
the postsynaptic neuron to homeostatically increase AMPA receptor numbers,
and despite Rab3A’s known role in vesicle trafficking, the predominant belief is
that its action is in the presynaptic neuron and not the postsynaptic neuron. If
Rab3A were located within the postsynaptic neuron and regulated AMPA
receptor insertion, it would provide a novel physiological role for Rab3A in the
postsynaptic neuron as well as establishing a new molecule involved in the
homeostatic upregulation of AMPA receptor levels.

IV. DISSERTATION SUMMARY

Specific Aim Conclusions
Specific Aim 1
1. Loss of Rab3A blocks the homeostatic increase in synaptic strength.
2. Mutation of Rab3A blocks the homeostatic increase in synaptic strength.

Specific Aim 2
A. Presynaptic Mechanism – Transmitter Concentration
1. γ-DGG sensitivity is independent of mEPSC amplitude and of TTX effect.
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2. Neurons with large mean amplitudes appear to have less neurotransmitter
or more receptors because the neuron with the largest mean amplitude
was the most sensitive to γ-DGG.
3. Neurotransmitter concentration varies widely within vesicles.

B. Postsynaptic Mechanism – GluR1-containing AMPA Receptors
1. NASPM inhibition of the homeostatic increase in mEPSC frequency
suggests that postsynaptic patches of receptors may not be
heterogeneous, but rather exclusively GluR1 or GluR2-containing.
2. GluR1-containing AMPA receptors have some involvement in the
homeostatic increase in mEPSC amplitude.
3. The TTX-induced increase in mEPSC amplitude in our preparation is not
due to a selective increase GluR1 receptor expression.
4. Loss of Rab3A does not prevent a modest homeostatic increase in GluR1
levels.
5. Multiple mechanisms may exist in the manifestation of the homeostatic
increase in mEPSC amplitude.

C. Postsynaptic Mechanism – GluR2-containing AMPA receptors
1. The homeostatic increase in GluR2 expression appears more consistently
than an increase in GluR1, but GluR2 involvement cannot fully explain the
homeostatic increase in mEPSC amplitude.
2. Loss of Rab3A may block the homeostatic increase in GluR2 levels.
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3. Multiple mechanisms may exist for the manifestation of homeostatic
increase in mEPSC amplitude.

Specific Aim 3
1. Loss of glial Rab3A does not block the homeostatic increase in mEPSC
amplitude.
2. Loss of neuronal Rab3A does block the homeostatic increase in mEPSC
amplitude.

Homeostatic synaptic plasticity provides synaptic circuits with the ability to
maintain stable functioning when faced with destabilizing perturbations in
synaptic activity that may arise from other plasticity mechanisms, such as LTP
and LTD. Since the discovery of homeostatic plasticity in 1998, much effort has
been devoted to exposing the mechanism underlying the nervous system’s ability
to compensate for chronic perturbations in synaptic activity. Consistent in many
studies is that the compensatory increase in synaptic strength in response to
chronic network silencing is accompanied by an increase in postsynaptic AMPA
receptors, but discrepancies exist as to whether GluR1 or GluR2 levels are
changed (see Table 1). Based on our findings presented here, we believe that
multiple mechanisms exist and no single mechanism can explain the
manifestation of the homeostatic change in synaptic strength. For example, in
our experiments we cannot conclude a selective regulation of GluR1 or GluR2
because both appear to contribute. Despite our evidence suggesting there is not
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a selective homeostatic increase in GluR1 vs. GluR2-containing AMPA
receptors, we have strongly demonstrated that the loss or the mutation of Rab3A
prevents the homeostatic increase in synaptic strength.
In Specific Aim 1 we definitively demonstrated that Rab3A is essential for the
manifestation of the homeostatic increase in mEPSC amplitude and that the
location of Rab3A’s action in homeostatic plasticity is in the neuron and not in the
glia (Specific Aim 3). When we attempted to determine the mechanism of
homeostatic plasticity so that we could then determine if loss of Rab3A disrupted
that mechanism, we ruled out a presynaptic mechanism (Specific Aim 2A) and
focused on postsynaptic modulation of AMPA receptors, specifically GluR1 and
GluR2-containing AMPA receptors (Specific Aim 2B and C), as substantial
evidence suggests an upregulation of AMPA receptors in response to chronic
network activity silencing (Table 1).
Initially we did not see an overall homeostatic increase in GluR1 expression,
but when we examined individual experiments for GluR1 involvement, we could
not rule out some involvement of GluR1-containing AMPA receptors because we
observed a small subset of cultures that did exhibit a homeostatic increase in
GluR1 expression (Figure 12A, right), and this modest homeostatic increase in
GluR1 levels was not prevented with loss of Rab3A. Electrophysiological
experiments with pharmacological blockade of GluR1-containing AMPA
receptors via NASPM further confirmed that there is a weak involvement of
GluR1 receptors in increasing mEPSC amplitude as neurons with the largest “top
25” mean trended towards increased NASPM-sensitivity (Figure 16D).
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Since upregulation of GluR1 receptors after chronic TTX treatment seemed
to have only a minor homeostatic role in our cultures, we tested whether GluR2containing AMPA receptor levels were increased after chronic activity silencing.
We discovered that GluR2 expression increased modestly with TTX-treatment
(Figure 18A) and that this modest increase in GluR2 expression was blocked in
Rab3A-/- cultures (Figure 18C). Despite the homeostatic increase in GluR2
expression being slight, we feel it correlates with our physiology data because
homeostatic increases in mEPSC amplitude are also small in magnitude. When
physiology was coupled with GluR2 immunohistochemistry experiments to
determine whether a correlation exists between increased mEPSC amplitude and
increased GluR2 expression and if Rab3A is involved, we found that 2 out of 3
Rab3A+/+ cultures and 1 Rab3A-/- culture demonstrated a relationship between a
homeostatic increase in amplitude and GluR2 expression (Figure 19A, B, C, and
D), and that the other 2 experiments on Rab3A-/- cultures blocked both the
homeostatic increase in amplitude and GluR2 levels (Figure 19I, J, K, and L).
The Rab3A-/- culture that exhibited both an increase in amplitude and GluR2
expression could be attributed to falling within the realm of an experimental
variability that is large in comparison to homeostatic changes that are small in
magnitude. In the Rab3A+/+ culture that showed a slight homeostatic increase in
amplitude despite a slight decrease in GluR2 expression (Figure 19E and F), we
believe this may hint at another mechanism of homeostatic plasticity as
suggested by another lab where a decrease in GluR2-containing AMPA
receptors shifts the ratio in favor of GluR1 receptors resulting in increased
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conductance that subsequently increase mEPSC amplitude (Garcia-Bereguiain
et al., 2013).
With all things considered, our data and the data previously published are
consistent with the presence of multiple mechanisms that can accomplish
homeostatic synaptic plasticity. This would explain the divergence in the field
about GluR1 vs. GluR2 involvement in homeostatic plasticity, and 2 studies have
shown that both GluR1 and GluR2 are homeostatically upregulated proportionally
(Table 1). Another possibility for the variability in finding GluR1 or GluR2
involvement in homeostatic plasticity, is that there could exist 2 phases, as
suggested for LTP (Plant et al., 2006), where the early initiation phase of the
homeostatic mechanism could involve insertion of GluR1 receptors, which are
eventually replaced by incorporation of GluR2 receptors into the membrane for
the maintenance of homeostatic plasticity. This could also explain why we did
not always see a homeostatic increase in GluR2 expression and saw an increase
in GluR1 levels in a small subset of experiments. Protocols for activity blockade
in previous studies range from 24 hours to 72 hours with the majority of studies
using a 24 hour or 48 hour block of activity (Table 1). The majority of those
experiments that used a 24 hour block to induce homeostatic plasticity observed
increased GluR1 expression, while most of the studies that showed a
homeostatic increase in GluR2 receptors blocked network activity for 48 hours
(Table 1). In our experiments, we blocked network activity via TTX treatment of
cultures for 2 days, and if there are phasic roles for GluR1 and GluR2 in the
initiation and maintenance of homeostatic plasticity, respectively, it may explain
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why we saw a more consistent homeostatic increase in GluR2 expression since
we performed our experiments during what would be the phase of GluR2
involvement. The 2 experiments where we saw increased GluR1 expression, or
the experiment where GluR2 did not increase, could be due to biological
variability around when the initiation phase segues into the maintenance phase.
Our results show that both GluR1 and GluR2 can increase in response to
chronic activity deprivation, but which predominates appears to vary from culture
to culture, and possibly, from cell to cell. In our preparation, a homeostatic
increase in GluR2 was more consistent, and with the exception of a strange
outlier with an unusually low level of GluR2 expression in the untreated culture
(Figure 18G and H), loss of Rab3A prevented the TTX-induced upregulation of
GluR2 receptors, but not GluR1 receptors. Based on our results that GluR1 and
GluR2 are both likely contributing to the manifestation of homeostatic synaptic
plasticity, that loss of Rab3A appears to prevent the homeostatic increase in
GluR2 but not GluR1receptors, and evidence of a biphasic mechanism in LTP
involving GluR1 and GluR2 AMPA receptors (Plant et al., 2006), we believe that
homeostatic plasticity occurs through a biphasic mechanism that is Rab3Adependent. We propose a model (Figure 21) that a chronic decrease in network
activity induces (Phase 1, ~ day 1) the homeostatic response by triggering glial
release of TNFα that signals to the postsynaptic neuron to increase GluR1containing AMPA receptors resulting in an increase in synaptic strength. This
increase in synaptic strength is maintained (Phase 2, ~ day 2) by initiating the
Rab3A-dependent release of BDNF that signals to the postsynaptic neuron to
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replace GluR1-containing AMPA receptors with GluR2-containing AMPA
receptors. Our model demonstrates a novel biphasic mechanism for the
manifestation of homeostatic plasticity, and most importantly, whatever the range
of underlying mechanisms of altered synaptic strength that can be triggered by
chronic activity blockade, synaptic strength cannot be modulated in the absence
of Rab3A.
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Figure 1. Potential mechanisms of homeostatic synaptic plasticity. Chronic
network hyperactivity could result in a decrease in presynaptic vesicle
neurotransmitter concentration (1) and/or removal of postsynaptic AMPARs
(2). Chronic network silencing may cause an increase in presynaptic vesicle
loading of neurotransmitter (3) and/or increased insertion of postsynaptic
AMPARs (4).
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Figure 2. The Rab GTPase cycle.
The Rab GTPase cycles between its
“on” GTP-bound form where it
associates with synaptic vesicles
targeting them to the cell membrane
and its “off” GDP-bound form where
it dissociates from vesicles.
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-/-

+/- +/+

Figure 3. Rab3A knock-out
genotyping by PCR. PCR
genotyping of Rab3A-/- (left
lane), Rab3A+/- (middle lane),
and Rab3A+/+ (right lane).
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A.

B.

Figure 4. Rab3A earlybird genotyping. A.
Rab3A ebd-targeted PCR. B. Restriction
digest of Rab3A ebd-targeted PCR amplicons
showing Rab3A+/+ (left lane), Rab3A+/ebd
(middle lane), and Rab3Aebd/ebd (right lane).
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Figure 5. Patch electrode on a
cultured cortical pyramidal
neuron.
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Figure 6. All mEPSCs recorded were
AMPA receptor-mediated. Blockade of
AMPA receptors via CNQX abolishes all
mEPSC activity which is restored upon
removal of CNQX.
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Figure 7. Normally functioning Rab3A is necessary for the homeostatic
increase in synaptic strength. A. Example recordings of Rab3A+/+ and
Rab3Aebd/ebd mEPSCs from control neurons and neurons grown in TTX for 2
days. B. Comparison of Rab3A+/+ and Rab3Aebd/ebd mEPSC frequency in
both conditions indicated revealed that Rab3Aebd/ebd diminished the significant
increase in frequency. * p = 0.030. C. The distribution of mEPSC amplitude
increases with TTX-treatment in Rab3A+/+ neurons (left) and this effect is
blocked in Rab3Aebd/ebd neurons (right). D. Quantification of mEPSC
amplitude demonstrates that Rab3Aebd/ebd abolished the activity-dependent
increase in amplitude. * p = 0.007.
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Figure 8. Rab3A is required for the homeostatic increase in synaptic strength.
A. Typical Rab3A+/+ and Rab3A-/- neuronal mEPSC recordings from cultures
treated for 2 days with TTX and untreated sister cultures. B. Quantification of
mEPSC frequency showing the diminished homeostatic increase in Rab3A -/neurons. * p = .005. C. The chronic TTX-induced shift to increased mEPSC
amplitude is lost in Rab3A-/- neurons. D. Rab3A-/- blocks the homeostatic
increase in amplitude. * p = 0.0004.
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Figure 9. Potential Rab3A-dependent
mechanisms for regulating the
homeostatic increase in synaptic
strength. Rab3A may increase synaptic
strength in a homeostatic manner by: (1)
increasing neurotransmitter concentration
loaded into vesicles, (2) regulating the
presynaptic release of a molecule that, in
turn, signals to increase postsynaptic
AMPAR expression, (3) trafficking
postsynaptic vesicles loaded with
AMPARs to the membrane, or (4)
controlling the release of glial-derived
factors that signal to increase
postsynaptic AMPAR numbers.
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Figure 10. Sensitivity to γ-DGG is independent of mEPSC amplitude and of
TTX effect. A. The mean percent reduction of mEPSC amplitude in response
to γ-DGG is not diminished in TTX-treated neurons. B. Scatter plot of each
cell’s γ-DGG-induced % reduction of mEPSC amplitude vs. its pre-γ-DGG
average amplitude demonstrating that the amount of γ-DGG inhibition is
independent of initial mEPSC amplitude and of chronic silencing via TTX (R2
= 0.08, p = 0.67). C. Example average mEPSC traces of individual neurons
showing a γ-DGG insensitive control cell with a small basal mean amplitude
(top, 15.0% reduction), a γ-DGG sensitive control cell with a large mean basal
amplitude (middle, 50.5% reduction), and a γ-DGG sensitive TTX-treated cell
with a large mean basal amplitude (bottom, 41.4% reduction).
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Figure 11. Example images of surface GluR1 staining in untreated and TTX-treated cultures.
Arrows indicate synapses (green = MAP2 (dendrite), red = GluR1, and white = VGLUT1). Scale
bars (white, lower right of each image) is equal to 5 μm.

Figure 12. Chronic TTX treatment has variable effects on surface
expression of GluR1-containing AMPA receptors. A. Left, quantification of
overall GluR1 puncta size in Rab3A+/+ cultures in response to TTX revealed
no changes. Right, breakdown of TTX effects on GluR1 cluster size of each
wild-type culture. B. Left, overall GluR1 intensity in wild-type cultures did
not change in response to TTX. Right, breakdown of TTX treatment on
GluR1 intensity of each wild-type culture.
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Figure 13. Individual experiment demonstrating a homeostatic
increase in a culture’s mEPSC amplitude is not accompanied
by an increase in that culture’s surface GluR1 expression. A.
TTX-induced increase in culture mEPSC amplitude. Scatter
plots of each dendrite’s GluR1 staining (open squares) and
their mean staining (filled squares) showing no change in B.
total GluR1 puncta size (left) or intensity (right), or C. synaptic
GluR1 puncta size (left) or intensity (right).
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Figure 14. A second experiment demonstrating the same
result as in Figure 13 – Despite a homeostatic increase in a
culture’s mEPSC amplitude, there is no associated increase in
that culture’s surface GluR1 expression. A. TTX-induced
increase in culture mEPSC amplitude. Scatter plots of each
dendrite’s GluR1 staining (open squares) and their mean
staining (filled squares) showing no change in B. total GluR1
puncta size (left) or intensity (right), or C. synaptic GluR1
puncta size (left) or intensity (right).
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Figure 15. A modest homeostatic increase in GluR1 expression is not
prevented by loss of Rab3A. A. Quantification of overall GluR1 puncta size
in Rab3A-/- cultures in response to TTX revealed a modest homeostatic
increase in GluR1 puncta size. B. Breakdown of TTX effects on GluR1
cluster size of each Rab3A-/- culture.
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Figure 16. Lack of inhibition of GluR1 homomers with NASPM further rules
out GluR1 as a major mechanism underlying the homeostatic increase in
synaptic strength. A. Bar graph showing NASPM does not block the TTXinduced increase in mEPSC amplitude. * p = 0.016, ** p = 0.008. B. Left
(Neuron 1), example histogram plot of a neuron exhibiting inhibition of the
homeostatic increase in mEPSC amplitude by NASPM highlighting the loss
of the largest events after NASPM (29.6% reduction, pre-NASPM mean
amplitude = 22.0 pA; red bars = distribution of pre-NASPM events, black
line = distribution of events with NASPM). Right (Neuron 2), in other cells,
amplitude was insensitive to NASPM (1.4% increase, pre-NASPM mean
amplitude = 18.6 pA). C. Bar graph showing NASPM inhibition of the
homeostatic increase mEPSC frequency (* p = 0.017, # p = 0.027, ** p =
0.006). D. Scatter plot showing a weak (R2 = 0.19) but significant (p =
0.01) correlation between the average of the largest 25 events and the
sensitivity to NASPM. E. NASPM often caused a clear reduction in
mEPSC frequency without affecting amplitude (traces are from Neuron 2,
above)
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Figure 17. Example images of surface GluR2 staining in untreated and TTX-treated cultures.
Arrows indicate synapses (red = GluR2, and white = VGLUT1). Scale bars (white, lower right of
each image) are equal to 5 μm.

Figure 18. Synaptic GluR2-containing AMPA receptors had a modest
homeostatic increase in expression that was blocked by loss of Rab3A.
Quantification of overall synaptic GluR2 puncta size in Rab3A+/+ cultures
showed a modest trend towards increasing after chronic TTX treatment
(A, left) that was less obvious in Rab3A-/- cultures (C, left). Line-series
plot of TTX effects on synaptic GluR2 cluster size of each Rab3A+/+
culture (A, right) and Rab3A-/- culture (C, right). Quantification of overall
synaptic GluR2 intensity in response to chronic TTX treatment revealed
no changes in Rab3A+/+ cultures (B, left) or in Rab3A-/- cultures (D, left).
Line-series plots of the TTX effect on synaptic GluR2 expression in
individual experiments on Rab3A+/+ cultures (B, right) and Rab3A-/cultures (D, right).
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Figure 19. Individual physiology-GluR2 immunohistochemistry correlation experiments. A, C, and E. TTX
effects on mEPSC amplitude from each Rab3A+/+ experiment, and their corresponding synaptic GluR2
expression profiles (B, D, and F; hollow squares represent single dendrites, filled squares represent means for
all dendrites in each condition). G, I, and K. mEPSC amplitude responses to chronic TTX treatment in
individual Rab3A-/- cultures, and their corresponding synaptic GluR2 immunohistochemistry experiments (H, J,
and L). Percent changes from untreated (CON) to TTX-treated (TTX) conditions are in red.

Figure 20. Neuronal Rab3A is responsible for the homeostatic increase
in mEPSC amplitude. A. Culturing strategy using glial feeder layers and
neurons from wild-type and Rab3A-/- mice. B. Wild-type (WT) neurons
grown on WT glia exhibit a homeostatic increase in mEPSC amplitude.
* p = 0.023. C. WT data from Figure 8 for reference of chronic TTX effect
on synaptic strength in our initial culturing strategy. D. WT neurons on
Rab3A-/- (KO) glia show a TTX-induced increase in mEPSC amplitude.
* p = 0.005. E. Loss of neuronal Rab3A (KO neurons on WT glia) blocks
the homeostatic increase in mEPSC amplitude. F. KO data from Figure
8 for reference showing that loss of Rab3A blocks the homeostatic
increase in synaptic strength in our initial cultures.
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Figure 21. Rab3A-dependent model of a biphasic mechanism for the
homeostatic increase in synaptic strength. Phase 1, or the Induction
Phase (~ day 1), is initiated by a chronic decrease in network activity (1)
triggering glial release of TNFα (2) that signals to the postsynaptic neuron
(3) to increase GluR1 incorporation into the membrane (4). In the
transition from day 1 to day 2 after activity blockade (5), Phase 2, or the
Maintenance Phase, is initiated by triggering Rab3A-dependent release of
BDNF from the presynaptic neuron (6), which travels across the synaptic
cleft activating a signaling cascade in the postsynaptic neuron (7) to
replace GluR1 receptors and increase GluR2 levels (8).
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NonsynapticCell
ular
Intensity
Synaptic
Nonsynaptic
Relative
fluorescence
Pharmacology

Table 1. Summary of studies examining the involvement of AMPA receptors in homeostatic
synaptic plasticity.
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Article

1° Antibody

Labels

Species

Conc.

Supplier

2° Antibody

Reactivity

Conc.

Supplier

anti-MAP2 (mono)

Soma & dendrites
Presynaptic
terminals
GluR1 receptor
Soma & dendrites
Presynaptic
terminals
GluR2 receptor

Mouse

1:300

Sigma

488

anti-mouse

1:225

Jackson

Guinea pig

1:4000

Chemicon

Cy3

anti-guinea pig

1:225

Jackson

Rabbit
Chick

1:10
1:2500

EMD Millipore
Abcam

Cy5 (649)
488

anti-rabbit
Anti-chick

1:225
1:225

Jackson
Jackson

Rabbit

1:4000

Synaptic Systems

Cy5

anti-rabbit

1:225

Jackson

Mouse

1:40

EMD Millipore

CY3

Anti-mouse

1:225

Jackson

anti-VGLUT1
anti-GluR1
Anti-MAP2
anti-VGLUT1
anti-GluR2

108

Table 2. List of antibodies used for immunohistochemistry experiments. GluR1 and GluR2 expression were
examined in separate experiments.

